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ABSTRACT 
CANNABINOIDS: 
A NOVEL TREATMENT STRATEGY FOR RETINAL 
NEURODEGENERATIVE DISORDERS 
Sandeep Samudre 
Eastern Virginia Medical School and 
Old Dominion University, 2007 
Directors: Dr. Frank A. Lattanzio Jr., and 
Dr. Patricia B. Williams 
Synthetic and naturally occurring cannabinoids are known to decrease intraocular 
pressure (IOP). Glaucomatous damage to the retina and optic nerve progresses even after 
therapy to maintain normal intraocular pressure (IOP). Topical application of 
cannabinoids decreases IOP while not affecting blood pressure or heart rate. Based upon 
their effects on other tissues, we hypothesize that these analogs reduce IOP and may also 
confer direct neuroprotective effects on the retina, possibly via CB1 and/or CB2 
receptors. The purpose of this study is to determine if the newly synthesized CB agonists, 
lipid soluble 0-1812 (CB 1), and water soluble 0-2545 (CB 1 « 2 ) are potent ocular anti-
hypertensive and neuroprotective. 
The IOP effects were tested in a rat glaucoma model, which was created Sprague-
Dawley rats by ligating 3 of 4 episcleral veins. IOP increased by at least 5 mm Hg in the 
operated eye, measured via Goldmann tonometry under sedation. Retinal damage was 
induced by injecting NMDA (2 ul of 10 mM) intravitreally in Sprague-Dawley rats. In 
other groups 0-1812 (2 mM) and 0-2545 (2mM) were co-injected with NMDA. 
Electroretinograms (ERG) were recorded at baseline, 1 wk and 2 wk after injection. 
Contralateral normal eyes served as controls. After 2 wk, retinas were flat mounted and 
stained with H&E. 
While both O-compounds showed significant IOP decrease lipid soluble 0-1812 
had the most rapid onset. 0-1812 was also effectively restricted a-wave amplitude loss; 
0-2545 was less effective. Retinal whole mounts of NMD A alone showed areas devoid 
of cells, while those treated with 0-1812 and 0-2545 were intact with an even 
distribution of retinal ganglionic cells. Considering both IOP and neuroprotective effects, 
lipid soluble 0-1812 was deemed to be most effective. 
Co-Directors of Advisory Committee: Dr. Peter F. Blackmore 
Dr. Stephen J. Beebe 
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Elevated intraocular pressure or ocular hypertension is a major risk factor for the 
development of glaucoma. Reduction of intraocular pressure (IOP) retards glaucoma 
1 9 
progression for both normotensive and ocular hypertensive patients ' . For this reason, 
current therapy is dominated by drugs that decrease IOP. Although drugs, such as beta 
adrenergic antagonists, carbonic anhydrase inhibitors, and cholinergic, alpha adrenergic 
or prostaglandin agonists, are currently prescribed to decrease IOP, they only indirectly 
alleviate glaucomatous damage. The causative factor for glaucoma related blindness is 
damage to the optic nerve and loss of retinal ganglion cells. 
The therapeutic effect of smoking Cannabis Sativa on IOP was first reported in 
the early 19th century3. This plant has more than 480 chemical constituents4. Of these, a 
group of at least 66 compounds that contain only carbon, hydrogen and oxygen are 
known collectively as cannabinoids 5. They represent a promising therapeutic class and 
have been proposed as treatment for a wide range of clinical disorders, including 
glaucoma. In 1971, Hepler and Frank reported that smoking marijuana lowers IOP by 25-
30% in a subset of subjects 6. Unfortunately, duration of action after smoking marijuana 
was relatively short, about 3-4 hours, but there appeared to be a dose-response 
relationship ' . Other ocular effects were conjunctival hyperemia, reduced tear 
production and an increase in pupil size 7. Concomitantly there are acute systemic effects 
This dissertation follows the style of Investigative Ophthalmology and Visual Science 
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induced by smoking marijuana, such as decreased blood pressure and tachycardia . In 
addition to decreasing IOP, cannabinoids may also have neuroprotective actions5'9. 
A major psychoactive constituent of cannabis, delta 9 - tetrahydrocannabinol 
(THC), produces many of its effects through activation of cannabinoid (CBi and CB2) 
receptors 10. These receptors normally respond to endocannabinoids, endogenous agonists 
that are synthesized and released by neurons on demand. Endocannabinoids may function 
as neurotransmitters, neuromodulators or synaptic messengers u . CBi receptors are 
largely present in brain, spinal cord, and certain peripheral tissues that include lung, 
heart, urogenital and gastrointestinal tract and the eye 12~14. Peripherally located CB2 
receptors are found in high concentration in cells and tissues associated with the immune 
system, such as the tonsils and spleen, as well as in retina5. 
Following the identification of endogenous cannabinoids and their receptors, 
numerous synthetic cannabinoids were synthesized. WIN-55-212-2 is the well-studied 
prototype for the aminoalkylindole synthetic cannabinoids that are structurally different 
from endogenous cannabinoids. WIN-55-212-2 activates both CBi and CB2 receptors, 
albeit with a proclivity for the CB2 receptors n. In normotensive rabbits, a single dose of 
either topical or systemic WIN-55-212-2 reduced IOP without apparent ocular toxicity 15, 
most likely through effects on CBi receptors 16. Another major group of 
endocannabinoids are the eicosanoids, of which anandamide is a prototypic member. 
When released in response to insult or injury, these endogenous substances provide 
analgesic and neuroprotective effects. Unfortunately, anandamide is rapidly hydrolyzed 
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by fatty acid amide hydrolase terminating its activity. Numerous studies with structure-
activity relationships have led to development of novel anandamide analogs, such as O-
1812. 
This dissertation focuses characterization of anandamide analog, 0-1812, and 
THC analog, 0-2545, in terms of their IOP reduction potential, neuroprotective effects 
and mechanism of action. Topical administration is emphasized to minimize adverse 
systemic and CNS effects. 
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CHAPTER II 
BACKGROUND AND AIGNIFICANCE 
Visual impairment, ranging from decreased acuity to blindness, is a major cause 
of morbidity, interferes with activities of daily living, and increases functional 
dependence, and is associated with a shorter life expectancy " . Based on the 2000 
census data, nearly 0.8% Americans over the age of 40 suffers from blinding disorders 
with an additional 2% with low vision. While those over 80 years of age make up 7.7% 
of the population, it is estimated that they account for 70% of blindness; this elderly 
segment represents the fastest-growing portion of the population20. As average life spans 
increase, age-related loss of vision will become a growing concern. 
There are a number of causes of low vision and blindness. The most common 
among Americans of varying ethnicities are age-related macular degeneration (AMD), 
cataracts, glaucoma, and diabetic retinopathy. Of these impairments, vision can be 
restored only in cataracts after surgical replacement with a prosthetic intraocular lens. 
The others AMD, glaucoma, diabetic retinopathy cause severe retinal damage and present 
significant obstacles in their treatment. 
Etiology and Pathology of Glaucoma 
Glaucoma is the second leading cause of blindness worldwide 5. Over 66.8 
million people have the condition, which has caused bilateral blindness in 6.7 million21. 
Fewer than 50% of glaucoma patients in first world countries know that they have the 
disorder, and even fewer are aware of it in developing countries . In the US, open-angle 
glaucoma is the leading cause of blindness in Hispanics with an added eight-fold increase 
in risk of blindness for African Americans 20. Primary open angle glaucoma is the most 
common form, presenting with elevated IOP and concomitant retinal damage. Although 
the etiology and pathological basis of glaucoma is not yet fully understood22, increased 
IOP remains a risk factor but not necessarily the cause. IOP increases when the aqueous 
outflow is compromised possibly due to the inhibition of the trabecular meshwork or by 
increased production of aqueous humor by the pars apparatus. This leads to a concordant 
increase in pressure across the lamina cribrosa and places stress on the axons of the 
retinal ganglion cells. While mechanical pressure might cause neuronal damage, 
increased IOP is neither necessary nor sufficient to cause neurodegeneration " . Other 
putative causative or contributing factors of glaucomatous neuropathy are local hypoxia 
due to a dysfunction in blood-flow regulation, excessive glutaminergic stimulation, 
oxidative stress, abnormal cellular pumps, and a compromised immune function 7. In 
addition to high IOP (>21 mmHg), risk of developing open angle glaucoma is increased 
by age, the ratio of the horizontal and vertical diameters of the optic cup to the optic disc, 
family history of open angle glaucoma, and a thin central corneal measurement28"33. 
Pharmacologic Therapies for Glaucoma 
It has been over a decade since a new class of pharmacologic agents was 
introduced for the clinical management of glaucoma . Currently available therapeutic 
approaches for the treatment of glaucoma include prostaglandin analogs, beta-adrenergic 
antagonists, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors and cholinergic 
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agonists. Each of these has a well known profile of clinical response and adverse effects. 
Even the first line agent for the treatment of glaucoma, timolol, as monotherapy 
controlled IOP in only 98 of 155 patients (63.2%)34. More recently, in the Ocular 
Hypertension Treatment Study, 40% of patients randomized to treatment required more 
than one medication to achieve the goal of a 20% reduction in IOP 35. Reduction of IOP 
retards glaucoma progression for both normotensive and ocular hypertensive patients ' . 
However, the rationale for reducing IOP to manage glaucoma does not adequately 
address the need to curtail neuronal loss. There is currently no efficacious treatment that 
directly addresses glaucoma induced neuropathy. 
Surgical treatment options for Glaucoma 
Lowering IOP either pharmacologically or surgically is the mainstay for 
glaucoma management. Pharmacological approaches remain the first line therapy in 
most cases of glaucoma. When multiple medications are ineffective or not tolerated, 
surgical approaches are implemented. Argon laser trabeculoplasty (ALT) is sometimes 
used as initial therapy in glaucomatous eyes. In this technique, 40-50 spots with a size of 
50 micron are placed radially around the trabecular meshwork with a short-term success 
rate of 65 - 97% " . More invasive surgical approaches include trabeculectomy, where 
a small portion of the trabecular meshwork is excised, and filtration surgeries, where a 
filtration bleb is created. As with all surgical approaches, complications due to wound 
healing or bleb failures are common and may require additional surgical interventions. 
Cannabinoids and Glaucoma 
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For over thirty years cannabinoids have been touted for their potential to decrease 
IOP 6. Unfortunately, cardiovascular and psychotropic adverse effects preclude systemic 
administration 40'41. Systemic administration of cannabinoids usually produces unwanted 
reductions in systolic and diastolic blood pressure, as well as decreased heart rate and 
variable changes in pupil diameter 42~44. Moreover, the associated dysphoric psychotropic 
effects of these agents are documented45. 
Cannabinoids and Neuroprotection 
Evidence for the neuroprotective properties of cannabinoids is based on research 
using mice and rat models of traumatic brain injury (TBI) 46. In the early post-traumatic 
events that follow TBI, ./V-methyl-D-aspartate (NMDA) receptors are activated leading to 
the presynaptic accumulation of glutamate and Ca (2+). The NMD A receptor is 
ionotropic which allows Na+, K+ and especially Ca (2+) ions to flow in and out of cells. 
Over activation of the NMD A receptor by glutamate and NMD A triggers excessive Ca 
(2+) entry into the cells disrupting the cellular homeostatic mechanisms targeting the cell 
for apoptosis 47"49. In glaucoma, the death of retinal ganglionic cells is proposed to be 
mediated by NMDA receptor induced excitotoxicity50. In response to these events, 
phospholipase C is activated, followed by the synthesis of diacylglycerol (DAG) and an 
endocannabinoid, 2-arachidonoyl glycerol (2-AG). Once 2-AG is released, it selectively 
activates cannabinoid receptors type 1 (CB1) to inhibit glutamate and Ca (2+) release, 
thereby protecting the neurons from excitotoxic damage. In a similar fashion, 
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anandamide, which is also an endocannabinoid produced on demand, has been 
demonstrated to protect rat cerebro-cortical neurons from ischemic damage. However, the 
endocannabinoids are hydrolyzed as rapidly as they are produced limiting the duration of 
effect. 
Evidence for endogenous cannabinoid production in the eye is sparse, although, 
the presence of CB1 receptors has been demonstrated in the trabecular meshwork and 
ciliary process tissues 13>51"53. Research done in the 1970's indicated severe retinal 
damage when monosodium glutamate (MSG) was injected in rat skin and eyes 5 '55. This 
damage was similar to that seen in glaucoma patients. Since then, several studies 
reported elevated glutamate levels in the vitreous humor as well as retinal Muller cells of 
glaucomatous eyes of humans and monkeys. Recently, the neuroprotective effect of the 
cannabinoid, delta 9-THC was demonstrated in a rat NMD A model of retinal 
neurotoxicity. In his study, El-Remessey induced retinal damage in rats by intravitreal 
injection of NMD A followed by intravenous administration of delta 9-THC 23. While 
their neuroprotective effect was clearly established, the safety and practicality of 
intravenous injection of a cannabinoid is of concern. Delta 9-THC is a potent 
psychoactive substance eliciting the characteristic tetrad effects, namely suppression of 
spontaneous activity, antinociception, hypothermia and catalepsy56. We believe that it is 
possible to circumvent these systemic effects by topical application of cannabinoids. To 
date, no reports that establish neuroprotection as a result of topical application of 
cannabinoids have been published. 
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Brief History of Cannabinoid Research 
Research on eannabinoids dates back to the 1700's, partly due to its extensive 
medicinal use in India and the East. Ingredients derived from the plant Cannabis Sativa 
were extracted as a resin (hashish) and were widely circulated for recreational purposes. 
In academic realms, a quest to identify and isolate the active components had already 
begun. In 1855, the Pharmaceutical society of Paris awarded Personne a prize for his 
extraction of a volatile oil from hemp 57. This attempt, albeit novel, did not produce 
C O 
meaningful results, as this oil was inactive and contaminated with toxic terpenes . 
Isolation of the active ingredient was complicated by the presence of numerous lipids in 
the mixture making the separation tedious and, in most cases, impossible. With 
limitations in the isolation techniques, composition of the active ingredient eluded 
scholars of the day. It was presumed that the active component was an alkaloid similar to 
that of opium 59. 
In 1975, the first cannabis alkaloid was identified. Cannabisativine was isolated 
form a Mexican variant of Cannabis Sativa. However, this form was still crude, and its 
biological activity in man was not established owing to its low concentration in the plant 
itself. Meanwhile, Gaoni and Mechoulam, isolated the main psychoactive ingredient, 
delta 9-THC using chromatography and NMR60. By the late 1970's most eannabinoids 
were isolated and a majority of its metabolic pathways defined59. Cannabinoid-based 
drugs were developed in the mid 1980's. For example nabilone was approved for use as 
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an antiemetic agent in the UK and later dronabinol in France as an appetite stimulant for 
AIDS patients61. 
Cannabinoid Receptors 
The pharmacological basis of cannabinoid action was assumed to be related to 
their high lipophilicity. Delta 9-THC is a potent lipophile and its biological activity 
considered to be similar to that of anesthetics and solvents. The isolates were racemic 
mixtures of delta 9-THC. Progress towards identification of a receptor-based system was 
hampered because of the assumption that their mechanism of action was similar to that of 
anesthetics rather than a receptor based system. In 1988, using tritium labeled 
cannabinoids, Howletts et al., identified a cannabinoid-based receptor. This discovery 
was an impetus for subsequently cloning the receptor 62. 
Strategies to clone the receptor were based on conserved sequence motifs to clone 
G protein-coupled receptors. Using this concept, resultant cDNA clones from rat brain 
were screened against its genome resulting in identification of a CB1 receptor specific for 
cannabinoids . This conserved sequence was screened in mouse and human genomes as 
well. In both rats and mice, this receptor encodes a protein made up of 473 amino acids 
64. In humans the sequence was identified to be 472 amino acids sharing a 97-99% 
sequence identity with rats and mice 65,66. The CB1 receptor is made up of seven 
transmembrane domains, resembling G protein coupled receptors in form and function 
(signal transduction). The CB1 receptor (mRNA and protein) is predominantly found in 
brain and neuronal tissue. 
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In 1993, Munro et al. cloned a new receptor from human HL-60 cells that bound 
delta 9-THC, aminoalkylindoles and eicosanoids. This 360 amino acid sequence was 
markedly different from the 472 amino acid sequence of the CB1 receptor. In fact, it 
shared only 48% homology with the CB1 receptor and 70-80% homology with other 
species. This new receptor was designated as a CB2 receptor. This receptor contains 
seven transmembrane domains and is predominantly found in spleen and immune tissues. 
Subsequently, genes for mouse and rat CB2 were cloned67'68. It should be noted that the 
rat gene is 13 amino acids longer at the carboxyl terminal than the mouse gene. 
Considerations for cannabinoid receptor agonist binding 
Successful cloning of the CB receptors has spawned numerous efforts to define 
agonist binding sites. The CB1 receptors comprised of seven transmembrane helical 
domains as well as a well conserved amino terminal extracellular domain containing 117 
residues 10. However, this long amino terminal domain does not play a major role in 
ligand binding or recognition 69. 
Successful binding of anandamide to CB 1 receptor is facilitated by lysine residue 
(position # 192) located at the extracellular end of helix three. Substitution of this residue 
with alanine eliminated anandamide binding and subsequent receptor activation, but had 
no effect on WIN55212-2 binding 16'70. WIN55212-2 is the well-studied prototype for 
the aminoalkylindole synthetic cannabinoids that are structurally different from 
endogenous cannabinoids. While substitution with arginine had little effect, glutamine 
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eliminated any binding71. The corresponding lysine in CB2 receptors is located at 
position 109 on helix three. Substitution of this lysine with arginine or alanine had little 
effect on receptor binding . 
Selectivity for agonist and antagonist binding can be localized to helices 4 and 5 
for both CB receptors. For agonist binding, a residue of interest is tryptophan at the 
extracellular end of helix 4. Substitution with alanine or leucine eliminated binding of 
most known agonists including WIN55212-2. The effect of anandamide binding was not 
studied in this model10. Selectivity for antagonist binding (SR141716A, CB1 antagonist) 
resides at the beginning of helix 5 68. 






Structure Activity Relationships 
Anandamide is one of five endogenous cannabinoid receptor agonists found in the 
mammalian brain73. It belongs to the eicosanoid group and characterized by 20:4, n-6 
series fatty acid amides (Figure 1)10 '74 '75. The most investigated to date have been 
anandamide and 2-arachidonoylglycerol (2-AG) . 
Activity of anandamide is similar to that of delta-9-THC in that is a partial CB1 
agonist with significantly less affinity for CB2 receptors ' . As a molecule, 
anandamide does not contain any chiral centers, a property that can be exploited to 
develop potent synthetic agents. Once released, anandamide is rapidly hydrolyzed by 
fatty acid amid hydrolase (FAAH) to produce arachidonic acid and ethanolamine. Martin 
et al. have proposed the following SAR's for developing potent synthetic CB1 agonists 
7Q 80 
based on the anandamide framework ' : 
1) Introduction of a methyl group on the 1 alpha carbon of anandamide resists the 
hydrolytic action of FAAH. 
2) Substitution of the amide with a two or three carbon chain is a requirement for 
activity. 
3) Activity is decreased if the hydroxyl is substituted. Substitution of the hydroxyl 
with an amino or carboxyl groups eliminates its activity. 
4) Metabolic stability is increased by the introduction of a methyl in the primary 
carbon adjacent to the carbonyl or nitrogen. 
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5) Structural changes in the arachidonoyl and ethanolamide moieties yield highest 
potencies. 
6) Activity is dramatically reduced if the chain length is decreased by two 
methylenes. 
Development of O-Compounds 
With these structure activity relationships defined, novel cannabinoid compounds, 
that are potent and highly selective for the CB receptors were developed by Organix Inc., 
(Woburn, MA), in collaboration with Dr. Billy Martin (Virginia Commonwealth 
University - Medical College of Virginia, Richmond, VA). Endocannabinoids like 
anandamide are produced in vivo in response to ocular injury but they are rapidly 
hydrolyzed by the enzyme FAAH. Anandamide is one of five endogenous cannabinoid 
receptor agonists found in the mammalian brain and also the most investigated to date, 
along with 2-arachidonoylglycerol (2-AG). Activity of anandamide is similar to that of 
delta-9-THC in that is a partial CB1 agonist with significantly less affinity for CB2 
receptors 69'76~78. As a molecule, anandamide does not contain any chiral centers, a 
property that can be exploited to develop potent synthetic agents. Once released, 
anandamide is rapidly hydrolyzed by fatty acid amid hydrolase (FAAH) to produce 
arachidonic acid and ethanolamine. The newly synthesized series of O-compounds 
include 0-1812 and 0-2545. Compared with anandamide, 0-1812 has higher affinity for 
the CB 1 receptor. The methyl substituent in the 1 alpha position reduces its susceptibility 
to hydrolysis by FAAH . Even though 0-2545 is a nonselective with respect to 
CB1/CB2 receptors, it has the advantage of being water-soluble. 
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Utilizing a metabolically stable anandamide analog, (R)-r-methyl-2'-hydroxy-
ethyl-arachidonamide (Met-anandamide), a l,r-dimethylpentyl-Met-anandamide 
construct was created and a cyano group was added to the C-20 atom to create 0-1812 
(Figure 2)79. By incorporating a methyl in the 1' carbon atom, 0-1812 is resistant to 
enzymatic degradation by FAAH. A cyano substitution gives 0-1812 a 500 - 1000 fold 
increased selectivity for the CB1 receptors over CB2, which is greater than the native 
anandamide 79. Anandamide-like cannabinoids, such as 0-1812, resist the development 
of tolerance, unlike delta 9-THC, suggesting a unique pharmacology that only partially 
overlaps with traditional cannabinoids 81. 0-1812 is also implicated in seizure modulation 
as it was determined to be a potent anticonvulsant . 
High lipophilicity associated with delta 9-THC, as well as other synthetic 
cannabinoids, is a constraint on solubility of these drugs. Cannabinoids require either 
surfactant or a water miscible substance, like albumin or Tween 80, to solubilize 80'83. A 
common vehicle used is a mixture of ethanol, Emulphor and saline, but even when 
dissolved in this vehicle, the cannabinoids will precipitate 84'85. It is impractical to use 
these vehicles in a chronic application scenario as the vehicle itself may contribute to 
adverse effects, for example chronic application of ethanol can lead to corneal 
debridement when applied topically. To avoid these pitfalls, numerous attempts to create 
water-soluble cannabinoids have been made. 
17 
/ 






Figure 2: Structures of 0-1812 and methanandamide 
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Zitko was successful in his attempt to prepare a water soluble cannabinoid . 
Delta 9-THC was converted to a morpholinobutyryl ester and conjugated with 
hydrochloride to make it water-soluble. Like its parent compound, this esterified 
compound retained its pharmacological activity. More recently, Martin et al. have 
developed cannabinoid compounds that are considerably potent than delta 9-THC, more 
specifically, 0-2545 87. Commercially available 5-cyano-dimethoxyresorcinol was a 
starting ingredient which was converted to a t-butyl dimethylsiloxy derivative and treated 
with an imidazole to produce 0-2545 87'88. Substitution with imidazole readily forms 
hydrochloride salts making the analogs water soluble and does not require metabolic 
conversion to an active molecule like ester analogs . This substitution also imparts a 
high CB1 affinity but even a higher CB2 receptor affinity. When dissolved in saline, O-
2545 was 40 fold more potent that delta 9-THC and was 20 times less lipophilic than 
delta 9-THC 87. 
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CHAPTER III 
HYPOTHESIS A N D SPECIFIC AIMS 
Glaucoma is a group of diseases that cause retinal and optic nerve damage. 
Although increased IOP is a contributing factor for glaucomatous damage, many people 
develop this damage with normotensive IOP. Although numerous pharmacologic agents 
are available to control elevated IOP, none directly address retinal and optic nerve 
neuropathy. This dissertation focuses characterization of the anandamide analog, O-
1812, and THC analog, 0-2545, in terms of their effect on IOP, neuroprotective effects 
and the mechanism of action responsible for these effects. Topical administration is 
emphasized to minimize adverse systemic and CNS effects. 
Preliminary studies/progress report 
These studies are designed based upon the suggestion by Green that 
endocannabinoids may have neuroprotective effects 42. We employed a novel technique, 
the electroretinogram (ERG), to provide in vivo evidence of neuroprotection in a rat 
NMDA model that mimics glaucomatous damage. 
Functional analysis of the retina through ERG: 
In diseases, like glaucoma, where the retinal integrity is compromised, ERG is an 
effective tool to assess the onset, severity and quantitate the loss of functional 
photoreceptors . By documenting the retinal response to light stimulation, this method 
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can accurately measure the functionality of photoreceptors and supporting retinal cells, 
such as amacrine cells. ERG records the electrical response to light stimulus in dark-
adapted eyes. Electrical responses, indicative of retinal function, are quantified and 
recorded electronically resulting in a waveform that is composed of a-waves, b-waves 
and oscillatory potentials (Figures 3). The a-wave represents activation of the rods and 
the b-wave the cones. 
Our preliminary ERG studies demonstrate, a diminished amplitude and 
corresponding area of both a- and b-waves after 2 wks of NMD A treatment, synonymous 
with glaucomatous damage (Figure 3), which are similar to those reported by Fortune et 
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Figure 3: ERG a- and b-waves 2 weeks after NMDA injection. 
Animals were dark adapted and stimulated with brief bright light flashes. 
Arrows indicate light stimulation. 
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Chronic treatment with synthetic cannabinoids: 
Our preliminary experiments suggest that over an extended period in an ocular 
hypertensive model, topically applied WIN 55212-2 is an effective and non-toxic ocular 
hypotensive agent 90. Rats were randomly assigned to either the WIN 55212-2 (Tocris, 
Bristol, UK) or vehicle treated group. For 4 weeks the right eye of 5 rats was treated 
topically three times per day between 8 AM to 6 PM, with 20 \il of WIN 55212-2 (0.5 
%). As a control using the same dosing regimen, 4 other rats were treated with 
Tocrisolve™ alone for 4 weeks (vehicle treated group). IOP, heart rate, and blood 
pressure were measured weekly, between the first and second daily doses. At the end of 4 
weeks, there was a 1-week washout period to determine if IOP returned to baseline. Rats 
were allowed to recover without drug or vehicle treatment for 1 week before the final 
measurements on week 5. 
Baseline IOP was 14.1 ± 0.6 mmHg in the operated eye; BP = 134±8/98±8 mm 
Hg; HR = 349±30 BPM. IOP decreased rapidly in the WIN-55-212-2 treated group. 
After one week of treatment IOP was 70% of baseline. IOP remained significantly 
decreased during the entire topical WIN-55-212-2 treatment period. The maximum 
decrease in IOP was seen after 3 weeks of treatment when IOP decreased to 47% of 
baseline. IOP returned to baseline (week 5) after the drug was discontinued (week 4) 91' 
. The vehicle, Tocrisolve™, alone had no effect on IOP. The cornea, conjunctiva and 
anterior chamber were normal with no signs of ocular inflammation. There were no 
effects on HR or BP, such as those associated with systemic administration. A more 
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comprehensive report ofWIN 55-212-2 effect on IOP after acute and chronic 
administration is included in chapter 9. 
Experimental design 
Specific aim #1: When applied topically, how effectively do cannabinoids penetrate the 
ocular structures? 
A relatively new method for the elucidation of pharmacokinetic profiles in vivo is 
microdialysis. It has been successfully utilized for regional sampling of low-volume 
compartments of many tissues, such as the brain, joints, kidney, and eye 93. By removing 
a minute amount of aqueous humor and re-perfusing an equivalent volume, microdialysis 
sampling allows for serial measurements of the aqueous fluid in order to create a 
complete concentration versus time curve for an individual subject. Rittenhouse et al 
used microdialysis sampling to produce intra- and inter-animal absorption profiles of 
propranolol after topical and intracameral injection, showing it to be an accurate and 
easily reproducible method93. In this study, we will use a similar method to examine the 
pharmacokinetics of lipophilic and hydrophilic O-compounds after topical ocular 
administration in an artificially perfused rat model. 
For artificial perfusion, Sprague Dawley rats will be first euthanized, a Y incision 
will be made to expose chest cavity. A cannula will be placed in the descending aorta 
and all systemic circulation will be blocked except for the internal carotid arteries. 
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Perfusion with PBS will be adjusted to maintain a carotid pressure of 90 mmHg. Dialysis 
probes will be placed in the anterior and posterior chamber of the perfused animal. The 
flow rate for the probes will be 1 ul/min and dialysate samples will be collected every 10 
min. Cannabinoid concentration will be quantified by HPLC, using a modification of the 
method described by Barberi-Heyob and colleagues, with a 5-um reverse-phase column 
(Prodigy 5 um ODS(2) analytical column, 150 x 4.6 mm, Phenomenex, Torrance, CA) at 
ambient temperature with a mobile phase of acidified acetonitrile water (pH = 4.0) 
solution94'95. The flow rate will be 1 mL/min with UV detection (254 nm). 
Chromatograms will be analyzed using Beckman System Gold software (Beckman 
Instruments, Inc., Fullerton, CA). 
Specific aim #2: Do endocannabinoid analogues reduce IOP? What is the preferred 
receptor type for this effect? 
Hypothesis: In previous experiments with WIN 55212-2 1%, IOP decreased by 30%. 
WIN 55212-2 is a mixed CB agonist. Because O-compounds are also CB agonists, we 
hypothesize that the O-compounds will be as efficacious as WIN 55212-2 in reducing 
IOP. 
Null hypothesis: If there is no decrease in IOP, then either the O-compounds are not 
efficacious ocular CB agonists or they are subject to rapid degradation i.e. they do not 
reach their intended targets at therapeutic concentrations. If this is the case then other 
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strategies of drug administration and synthesis of more potent analogs need to be 
considered. 
To determine the receptor that is responsible for the IOP effect, selective CB1 
antagonist, e.g. SR141716A, or a selective CB2 antagonist, e.g. SRI44528, will be used 
to block the ocular effects of the agonist. To establish the mechanism of action including 
correlation between efficacy and effects on CB1 and CB2 receptors, other rats will be 
retreated with either a CB1 or CB2 receptor antagonist before topical treatment with the 
nonspecific receptor agonists as described above. 
Specific aim #3: Do endocannabinoid analogues confer neuroprotection as reflected by 
changes in the ERG? Which receptor (CB1 or CB2) participates in the neuroprotective 
effect? 
Hypothesis: In the amygdala, CB agonists 0-1812 and 0-2545 are neuroprotective. In 
the CNS or in neural tissues, they decrease oxidative damage and also increase neuroglial 
proliferation ' . The retinal ganglionic cells are of glial origin and, therefore, we 
hypothesize that the retinal ganglionic cells would show similar profiles. However, in the 
ocular environment proliferation of the retinal ganglionic cells is not possible due to 
physiological constraints. Thus, only the neuroprotective effect of these CB agonists will 
be evaluated in our NMDA model. 
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Null Hypothesis: If these drugs do not show functional neuroprotection, then the retinal 
ganglionic cells have an environmental constraint that restricts them from responding like 
their progenitors. Other strategies, such as cell culture experiments, will be needed to 
determine if, indeed, the ocular environment is the constraint. 
Rats will be randomly assigned to one of 4 treatment groups (Table 1). Some rats 
will be pretreated with topical application of either O-1812, a lipid soluble CB analog, or 
0-2545, a water soluble CB analog. In our prior experiments with glaucomatous rats, 
both significantly decreased IOP. For the two treatment groups, each rat will receive 3 
doses at 2 hour intervals before injection of NMD A. Both the untreated control and 
positive control will receive phosphate buffered saline (PBS) using the same treatment 
regimen. 
The primary criterion for assessing neuroprotective effects of CB analogs includes 
a significant preservation of the ERG waves. ERG measurements will be performed at 
baseline and at 1 and 2 weeks following administration of NMD A. Rats will be sacrificed 
after 2 weeks for morphological analysis of the retina including retinal ganglionic cell 
counts. Groups treated with CB analogs should have a decrease in IOP without systemic 
effects, e.g. stable heart rate and blood pressure. 
In the amygdala, 0-1812 and 0-2545 have exhibited neuroprotective effects 
through activation of CB receptors 96. In the eye, in addition to the CB 1 receptor, a CB2 
receptor is also implicated. If neuroprotection is observed in the eye, then we will 
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determine which receptor (CB1 or CB2) is activated to elucidate the mechanism of 
neuroprotection. 
These experiments will determine whether the effects of each efficacious 
cannabinoid are mediated via CB receptors. Receptor activity will be inferred based on 
the ability of either a selective CB1 antagonist, e.g. SR141716A, or a selective CB2 
antagonist, e.g. SR144528, to block the ocular effects of the agonist. To establish the 
mechanism of action including correlation between efficacy and effects on CB1 and CB2 
receptors, other rats will be retreated with either a CB1 or CB2 receptor antagonist before 
topical treatment with the nonspecific receptor agonists as described above. If 
neuroprotection is not mediated via the CB receptor system, then other likely areas of 
interest would be to study the antioxidative effects of these drugs. 
In addition to the activation of CB receptors, the mechanism of action needs to be 
further elucidated by studying Ca [2+] influx into the retinal ganglionic cells. When 
NMDA binds to its receptor, it triggers Ca [2+] entry into cell. This produces increased 
calcium binding to the intracellular ryanodine receptor-coupled Ca [2+] channel and 
subsequent increase in Ca [2+] released from the endoplasmic reticulum (ER). Increased 
Ca [2+] will eventually lead to apoptosis (Figure 4). Hypothetically, CB agonists reduce 
intracellular Ca [2+], thus mitigating the effects of increased Ca [2+] caused by NMDA. 
This effect is mediated via CBl/G-protein coupled inhibition of adenylyl cyclase. In this 
preliminary study, the intracellular Ca [2+] will be monitored after treatment with 


















Figure 4: Proposed pathway leading to retinal ganglionic cell loss due to apoptosis. 
Arrows indicate site of action for cannabinoids. 
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Specific aim #4: Because they have a different mechanism of actions, is there an additive 
effect on IOP by combining O-compounds with currently available glaucoma 
medications? 
As described in the introduction, currently available therapeutic approaches for 
the treatment of glaucoma focus mainly on the reduction of IOP. However, up to 50% of 
patients cannot be maintained on single drug therapy; most require use of two or even 
three drugs to control their IOP 97. Commonly used classes of agents are (3-adrenergic 
antagonists (timolol), a-adrenergic agonists (brimonidine), prostaglandins (travoprost) 
and carbonic anhydrase inhibitors (dorzolamide). Timolol lowers IOP by decreasing 
aqueous humor production while brimonidine, in addition to decreasing aqueous humor 
production, has the added benefit of increasing uveoscleral outflow98'". Dorzolamide 
reduces aqueous humor formation while prostaglandins increases uveoscleral outflow 100' 
101. We hypothesize that O-compounds are more efficacious than the currently available 
agents. 
The primary purpose of this study is to compare efficacy of timolol, dorzolamide 
or brimonidine as monotherapy or in combination with endocannabinoid analogs, 0-1812 
or 0-2545, in a rat glaucoma model. All drugs will be administered individually and IOP 
measured using a Tonolab™, a new instrument specifically designed to measure IOP in 
rats and mice. For combination therapy, timolol, dorzolamide or brimonidine will be 
administered first followed by 0-1812 or 0-2545. For all conditions, IOP will be 
measured 30, 60 and 120 min after drug administration. 
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CHAPTER IV 
METHODS AND MATERIALS 
Animal Subjects 
All studies were conducted in accordance with the Principles of Laboratory 
Animal Care (NIH Publication No. 85-23, revised 1985), the OPRR Public Health 
Service Policy on the Humane Care and Use of Laboratory Animals (revised 1986), the 
U.S. Animal Welfare Act, as amended, as well as the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. Protocols were approved by the Eastern 
Virginia Medical School (EVMS) Institutional Animal Care and Use Committee. 
Rat Ocular Hypertensive Model 
In human glaucoma, a gradual progression of IOP leads to various retinal deficits. 
This condition can be mimicked in an animal model by ligation of major outflow vessels. 
To elevate IOP, male rats weighing ~ 200 gm (14 Sprague Dawley, 4 Brown Norway, 5 
Long Evans and 5 Wistar) underwent vortex vein ligation (Harlan, Indianapolis, IN). 
Surgeries were performed on the right eye (OD) while the contralateral left eye (OS) 
served as a normal non-operated control. A detailed explanation of the surgical technique 
is described in chapter 5, the development of a rat ocular hypertensive model. 
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Rat N-methyl-D-aspartate (NMDA) model 
As a model to induce reproducible damage to the photoreceptors and retinal 
ganglionic cells, male Sprague Dawley rats weighing ~ 200 gm were injected 
intravitreally with 2 ul of 10 mM NMDA. All injections were made in the right eye (OD) 
while the contralateral left eye (OS) served as a normal non-modified control. In these 
experiments only damage to the photoreceptors was measured as a function of ERG a-
wave amplitude. Although retinal damage was evident within 24 hours of NMDA 
injection, only 2 week measurements were reproducible. 
Measurement of IOP 
IOP response is a primary outcome measure for drug efficacy. Although IOP can 
be measured with a variety of instruments, accurate measurements can only be obtained 
by applanation or direct rebound tonometry. In this dissertation, Goldmann applanation 
tonometry and an electromagnetic piston rebound Tonolab® will be used to directly 
measure IOP. 
Goldman applanation tonometer: 
IOP measurements were performed under mild sedation (ketamine 40 mg/kg and 
acepromazine 6 mg/kg) with a custom machined Goldmann applanation tonometer. 
Two readings per eye were taken at each time interval, and averaged. Although Cohan 
and Bohr reported Goldmann applanation in the conscious Brown Norway rat, other 
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strains were not as docile . We found that firm restraint of the conscious rats increased 
variability. To reduce the likelihood of erroneously elevated IOP readings secondary to 
the Valsalva maneuver, mild sedation was used. 
Tonolab®: 
In chapter 9, IOP measurements were made with a Tonolab® (Colonial Medical 
Supply Co. Inc., Franconia, NH). To reduce the likelihood of erroneously elevated IOP 
readings secondary to the Valsalva maneuver, mild sedation was used (ketamine 40 
mg/kg and acepromazine 6 mg/kg). 
Electroretinogram (ERG) 
ERG is a non-invasive measure of retinal function. Damage to the different layers 
of the retina can be assessed by quantitating the amplitude of the a-waves (photoreceptors 
and bipolar cells) and b-waves (inner retinal function). This test can be performed 
photopically (light adapted) or scotopically (dark adapted). Maximal retinal response can 
only be obtained scotopically. In this dissertation, scotopic ERG was used to determine 
retinal function for the ligated ocular hypertensive model as well as experiments with 
NMDA model. Scotopic ERG changes were measured only at terminal points (32 - 72 
weeks) in Sprague Dawley rats with sustained IOP elevation (n=10) to determine the 
extent of retinal damage. For the NMDA model, ERG's were obtained at 1 and 2 weeks 
after NMDA injection. NMDA was also used as a positive control in other experiments, 
which reduces the amplitude of both a- and b-waves 89. 
ERG Procedure: 
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Rats were dark adapted for at least 4 hr. Eyes were dilated with atropine (1%, 
Falcon Pharmaceuticals, Fort Worth, TX). To restrict rat mobility, they were 
anesthetized with acepromazine (12 mg/kg, IP) and ketamine (80 mg/kg, IP) followed by 
topical proparacaine (0.5%) and methylcellulose gel (GPS 2.5%, Wilson Ophthalmic 
Corp, Mustang, OK). Custom made AgCl electrodes (Warner Instruments, Hamden, CT) 
were placed on the apex of the cornea. Stimuli consisted of 10-usec flashes of 
unattenuated white light (30 cd/mm) generated by a Ganzfeld bowl photo stimulator 
(Grass Instruments, PS22, Quincy, MA). ERG's were recorded separately in each eye, 
while the contralateral eye was covered with an eye patch. ERG responses were 
differentially amplified (1-1000 Hz) with a driver amplifier (Grass Instruments, Model 
7DAF Polygraph, Quincy, MA). Data were acquired digitally via DASYLab® (Bedford, 
NH). The contralateral normal eye served as an age matched negative control, e.g. 
response in a normal, undamaged eye. Differences in amplitude of the a- and b-waves 
between the operated eye and the contralateral eye were calculated and analyzed. 
Fundus Examination 
In glaucoma, severe degeneration of the retina and optic nerve contribute to an 
increase in the size of the optic cup relative to the optic disc. A fundus examination can 
detect changes in the optic cup and disc. With electronic documentation of the fundus, 
accurate cup to disc ratios to estimate the severity of glaucoma can be obtained. 
Glaucomatous changes in the fundus were observed by slit-lamp examination on 
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anesthetized rats. Retinal images were recorded with a 3.2 mega pixel digital camera 
(PowerShot SI IS, Cannon, Tokyo, Japan) retrofitted to a slit lamp (Zeiss, Germany). 
Full resolution images were obtained with a constant optical zoom (10 X) and processed 
with Metamorph™ image analysis software. Cup to disc ratios were obtained for area, 
height, and width using Metamorph™ image analysis. For area measurements, the outer 
edge of the cup and disc were selected, pixels were counted, and the cup to disc ratio was 
determined. For individual height and width cup to disc measurements, diameters for 
each was obtained through a central plane. The ratios were then expressed as the cup 
diameter to the outer disc diameter. 
Assessment for ocular irritation 
Assessment of ocular irritation is possible by careful observation of anterior 
segment structures with the use of a slit lamp. Each structure of the anterior segment is 
evaluated for signs of inflammation and quantitated using a semi-quantitative scale as 
developed by MacDonald and Shadduck 103. In our experiments, slit lamp examination 
(HAAG-STREIT, Bern, Switzerland) was performed by an independent knowledgeable 
observer using a modified MacDonald-Shadduck Semi-quantitative Scale for Ocular 
Irritation 104. The exam was conducted at the beginning and end of each experiment to 
determine if the topical application of cannabinoids or vehicle caused ocular irritation. 
Each eye was assessed for signs of inflammation, conjunctival chemosis/swelling, 
conjunctival discharge, aqueous fibrin/flare, loss of the corneal light reflex, obscuration 
of iris structures, and corneal opacity/vascularization/staining. They were rated on a 4 
point scale where 0 represented normal. 
Confocal Examination 
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In the past, invasive histological techniques such as scanning electron microscopy 
were necessary to obtain detailed corneal (epithelium and endothelium) morphology. As 
with any histological technique the tissue has to be excised and longitudinal 
measurements are not possible. With confocal microscopy, the cornea can be optically 
sectioned making it possible to visualize and electronically document the corneal 
epithelium, stroma and endothelium. In addition, this method is non-invasive making it 
possible to obtain multiple measurements on the same subject during the study period. In 
this dissertation, repeated noninvasive in vivo visualization of cornea and anterior 
segment for the presence, location and number of inflammatory cells, as well as fibrin, 
hyper-refractile bodies and changes in stromal and endothelial cell morphology was 
performed by confocal microscopy (ASL 1000, Advanced Scanning Limited, New 
Orleans, LA), documented using a CCD camera (Kappa Opto-electronics Inc, Monrovia, 
CA) and recorded with SVO-9500MD VCR (Sony Corporation, Tokyo, Japan). Prior to 
applanation, rabbits were sedated with acepromazine, 2.5 mg/kg, and ketamine, 25 
mg/kg, plus topical administration of 0.5% proparacaine. A surface scan was performed 
to verify proper applanation. Corneal thickness, epithelium, stroma, endothelium and 
aqueous chamber were optically sectioned in at least 3 representative areas. Endothelial 
cell shape changes, infiltration of inflammatory cells into the corneal stroma and anterior 
chamber were documented. At least 4-6 trans-corneal scans were collected for analysis 
using the Metamorph® imaging system (Universal Imaging, Downingtown, PA). Three 
readings were averaged to calculate corneal thickness. 
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Heart rate and blood pressure 
Heart rate and blood pressure were used to evaluate potential systemic effects of 
topically applied CB agonists and adrenergic antagonists. A standard tail cuff apparatus 
was used to measure heart rate (HR) and blood pressure (BP) on sedated rats. A pulse 
amplifier (Model 29, IITC, Woodland Hills, CA) was placed in line for digital data 
conversion. Data were processed with DasyLab® generated analysis module (Version 
6.0, Dasytech, Amherst, NH). 
Histology 
Histologic examination accurately documents any morphologic changes during 
the study period. In this dissertation, histology was performed on retinal flat mounts and 
retinal cross sections to obtain RGC counts as an adjunct measure of neuroprotection. 
Histology for retinal flat mounts: 
Eyes were enucleated and fixed in 10% phosphate buffered formalin (Fisher 
Scientific, Fair Lawn, NJ) for at least 1 wk. For retinal whole mounts, retinas were 
harvested by bisecting the eyes peri-limbally and removing the anterior segment. The 
remaining posterior segment cup was flattened with 4 radial cuts after which the retinal 
layer was carefully dissected from the underlying choroid and sclera. The flattened retina 
was placed vitreal-side up on glass slides (Fisherbrand Superfrost, Pittsburg, PA), 
embedded in Aqua-Mount® (Lerner Laboratories, Pittsburg, PA), and stained with 10 X 
dilutions of Hematoxylin and Eosin. For positive identification of RGC, retinal flat 
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mounts were compared with cross-sections for cell shape, placement and distribution. 
All slides were digitally photographed (Opelco) and quantitatively analyzed with Sigma 
Scan (Systat Software Inc., Richmond, CA). Cell counts were performed by 
knowledgeable masked observers. For each retina, at least 2 microscopic fields of 50 
um2 were captured per quadrant at predetermined distance from the optic cup (200 um). 
The total retinal area was approximately 500 um2. RGC counts were averaged for each 
field and comparisons made between operated, contralateral control and positive control 
NMDA treated eyes. Retinal cell counts are expressed as cells per 50 um2±SD. 
Histology for retinal cross-sections: 
Operated and contralateral control eyes were enucleated and fixed in 10% 
phosphate buffered formalin (Fisher Scientific, Fair Lawn, NJ) for at least 1 week. For 
retinal cross sections, whole eyes were embedded in cryo media (Tissue-Tek® O.C.T. 
Compound, Sakura, Torrance, CA). Sections of 40 um thickness, at the level of the optic 
nerve head, were cut and mounted on superfrost glass slides (Fisherbrand Superfrost, 
Pittsburg, PA), and stained with hematoxylin and eosin. The slides were digitally 
photographed at 20X magnification. Retinal ganglionic cell counts were performed on 
200 um sections of the retina, for a total retinal length of approximately 12 mm 
documented at 20X magnification. Retinal cell counts are expressed as cells per 200 um 
± SD. All quantitations were performed with SigmaScan® (Systat Software Inc., San 
Jose, CA) 
RGC-5 Cells 
RGC-5 Cells were obtained from Dr. Neeraj Agarwal, University of North Texas 
Health Science Center, Fort Worth, TX. They are retinal ganglionic cells isolated from 
Sprague Dawley rat retinas and then transformed into a \|/2 El A viral vector. The 
transformed RGC-5 cells share similar characteristics with native RGC cells in that they 
express Thy-1 and Brn-3C and are sensitive to glutamate excitotoxicity and neurotrophin 
withdrawal105. 
Ca [2+] Measurements 
Glutamate excitotoxicity induced by NMDA causes cells to mobilize Ca [2+] and 
initiate the apoptosis pathway. It is hypothesized that cannabinoids prevent the 
mobilization of Ca [2+] thereby preventing cellular apoptosis. Measuring Ca [2+] influx 
in the retinal cells is therefore necessary to understand the mechanism of action of the 
cannabinoids. RGC-5 cells were plated on a 96 well plate (BD Falcon, Franklin Lakes, 
NJ) until confluent. All cells were then treated with NMDA (ImM). After NMDA 
treatment, some cells were incubated with 10 uM of either O-1812 or 0-2545 for 1 hr. 
Intracellular calcium was measured using fura-2/AM (Molecular Probes, Eugene, OR). 
Cells were loaded with fura-2 (2 mM) at the beginning of the experiment and Ca [2+] 
measurements were made at baseline, 30 and 60 min after drug treatment using a 
SpectraMAX™ Gemini (Sunnywale, CA) spectrofluorometer (excitation wavelength of 
340 nm and 380 nm and an emission wavelength of 505 nm). At the end of the 
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experiment, all cells were incubated with, A23187 (Calcimycin, Cole Parmer, Vernon 
Hills, IL) a calcium ionophore, after which a final Ca [2+] measurement was made. 
Materials 
0-1812 and 0-2545 were obtained from Dr. Billy Martin, Virginia 
Commonwealth University, Richmond, VA. 0-1812 was directly dissolved in 
Tocrisolve™, a proprietary 1:4 soya oil/water emulsion (vehicle, Tocris Bioscience, 
Bristol, United Kingdom). 0-2545 was dissolved in phosphate buffered saline. Sutures 
were obtained from Sharpoint (Reading, PA). Timolol was purchased from Falcon 
(Napa, CA). WIN55212-2 was directly dissolved in Tocrisolve™, as was the CB1 
antagonist, SR141716, and the CB2 antagonist, SR144528. SR141716 and SR144528 
were generously supplied by the National Institutes of Health (Bethesda, MD). 
Travatan® (travoprost, 0.004%, Alcon, Fort Worth, TX), Trusopt® (dorzolamide, 2%, 
Merck & Co Inc., West Point, PA), and Alphagan® (brimonidine, 0.1%, Allergan, Irvine, 
CA) were donated by the Lion's Eye Clinic, Norfolk, VA. 
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Statistical Analysis 
Student's t-test was used to compare data from RGC cell counts and changes in 
the HR, BP and ERG amplitude. A one-way ANOVA analysis was performed to 
compare IOP between treatments with 0-1812, 0-2545, WIN55212-2, timolol. Other 
statistical tests are specified in the results section. A difference ofp < 0.05 was 




DEVELOPMENT OF A RAT OCULAR HYPERTENSIVE MODEL 
Introduction 
As previously noted, it is widely accepted that an increase in IOP is a major risk 
factor for primary open angle glaucoma 106. Despite some recent evidence to the contrary, 
the therapeutic interventions proven to consistently retard the progression of glaucoma 
are those that decrease IOP 107~110. To study newer pharmacologic interventions, a valid 
experimental model should mimic both pathologic and physiologic characteristics of 
glaucoma, including sustained elevated IOP with evidence of retinal damage. 
Most published animal glaucoma models elevate IOP only transiently and are 
therefore not suitable for long-term pharmacokinetic and pharmacodynamic studies 
(Table 2). Transient rapid IOP elevation is less characteristic of primary glaucoma, 
where gradual changes in IOP, retinal function and optic nerve morphology are 
pathognomonic. Currently available approaches to gradually increase IOP include 
occlusion of aqueous humor outflow by laser treatment of the trabecular meshwork, 
repeated intracameral injection of hyaluronic acid, injection of hypertonic saline or 
cauterization of the vortex veins (Table 2). With these approaches, a primary limiting 
factor is a short-lived IOP elevation that does not mimic the common clinical course, 
rendering these models unsuitable for long term studies. 
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The purpose of the present study was to devise a surgical technique that provided 
a constant, long term IOP elevation with concomitant evidence of retinal and optic nerve 
damage. We hypothesized that by minimizing surgical trauma during exposure and 
ligation of the vortex veins, a stable ocular hypertensive rat model suitable for long term 
pharmacodynamic and pharmacokinetic studies can be obtained. Further, we 
hypothesized that differences in strains might contribute to differences in the magnitude 
and duration of IOP elevation. Four strains of rats, Sprague Dawley, Brown Norway, 
Long Evans and Wistar, were compared to determine if some strains were more suitable 
models than others. 
44 



















































































































Morrison et al. 
Johnson etal.113 











Grozdanicet. al. ' 
124 
Mittag etal.125 
Hosseini et al.90 
Yuetal.126 
* NR = not reported 





Male rats weighing ~ 200 gm (14 Sprague Dawley, 4 Brown Norway, 5 Long 
Evans and 5 Wistar) underwent vortex vein ligation (Harlan, Indianapolis, IN). Surgeries 
were performed on the right eye (OD) while the contralateral left eye (OS) served as a 
normal non-operated control. 
Surgical Procedure 
Rats were anesthetized with acepromazine (12 mg/kg, IP, Boehringer Ingelheim 
Vetmedica, Inc., St. Joseph, MO) and ketamine (80 mg/kg, IP, Phoenix Scientific, Inc., 
St. Joseph, MO) followed by topical proparacaine (0.5%, Wilson Ophthalmic Corp, 
Mustang, OK) and a lateral canthotomy was performed. After visually identifying the 
vortex veins through the conjunctiva and overlying rectus muscles, Westcott scissors 
were used to incise only conjunctiva immediately surrounding the vein. Minimal blunt 
dissection was performed to isolate the vessel from Tenon's capsule. Once exposed, the 
vessel was ligated with 9-0 nylon suture. Distention of the vessel indicated a complete 
ligation. The same procedure was repeated on two other vortex veins. The canthotomy 
was closed using 7-0 silk suture with prophylactic topical administration of tobramycin 
(0.3 %, Bausch & Lomb Pharmaceuticals, Inc., Tampa, FL) and loteprednol (0.5%, 
Bausch & Lomb Pharmaceuticals, Inc., Tampa, FL). Buprenorphine (0.05 mg/kg, IP, 
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Benckiser Pharmaceuticals, Inc., Richmond, VA) was administered immediately after 
surgery and 24 hr afterwards. Sham surgeries were performed in Sprague Dawley rats 
(n=4) where, after lateral canthotomy, the veins were exposed but not ligated. Surgeries 
on New Zealand White Rabbits were performed in a similar fashion. 
IOP was measured using_Goldmann applanation tonometry was employed using a 
custom machined applanator (Haag-Streit, Bern, Switzerland). Measurements were made 
at the same time of day and by the same observers. IOP measurements reported are 
averages of two consecutive readings. Baseline IOP was measured on three separate 
occasions during the week before surgery. Based on the rate of increase and sustained 
elevation of IOP in Long Evans and Sprague Dawley rats, IOP was measured weekly in 
other strains for 4 weeks and monthly thereafter. Rats were lightly sedated with ketamine 
(20 mg/kg) and acepromazine (3 mg/kg). Although Cohen and Bohr reported Goldmann 
applanation in conscious Brown Norway rats, other strains were not as docile 102. In their 
protocol, firm restraint was required which decreased the reproducibility of the 
measurements. In our series, however, even mild sedation was not without risk as 
mortality related to repeated sedation occurred in four of 14 Sprague Dawley rats over a 
40 week period; one of four Brown Norway rats over 16 weeks, and one of five Long 
Evans rats over a 6 week period. 
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Primary Outcome Measure 
Rats with a consistent difference of >5 mm Hg between the operated eye and the 
contralateral control eye were included in the study. 
Treatment with Timolol 
In the rats with sustained ocular hypertension, the response to standard 
antiglaucoma therapy was measured. Rats with ocular hypertension, sustained for at least 
6 weeks, were treated with a single topical administration of 20 ul of timolol (0.5%, 
ISTA Pharmaceuticals Inc., Irvine, CA) to the hypertensive eye. IOP in the treated eye 
and in the untreated normal contralateral eye was measured every 30 minutes over a 2 hr 
period. 
Scotopic ERG changes were measured only at terminal points (32-72 weeks) in 
Sprague Dawley rats with sustained IOP elevation (n=10) to determine the extent of 
retinal damage. Rats were dark adapted for at least 4 hr. Eyes were dilated with atropine 
(1%, Falcon Pharmaceuticals, Fort Worth, TX). Rats were anesthetized with 
acepromazine (12 mg/kg, IP) and ketamine (80 mg/kg, IP) followed by topical 
proparacaine (0.5%) and methylcellulose gel (GPS 2.5%, Wilson Ophthalmic Corp, 
Mustang, OK). Custom made AgCl electrodes (Warner Instruments, Hamden, CT) were 
placed on the apex of the cornea. Stimuli consisted of 10-usec flashes of unattenuated 
white light (30 cd/mm) generated by a Ganzfeld bowl photo stimulator (Grass 
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Instruments, PS22, Quincy, MA). ERG's were recorded separately in each eye, while the 
contralateral eye was covered with an eye patch. ERG responses were differentially 
amplified (1-1000 Hz) with a driver amplifier (Grass Instruments, Model 7DAF 
Polygraph, Quincy, MA). Data were acquired digitally via DASYLab (Bedford, NH). 
The contralateral normal eye served as an age matched negative control, e.g. response in 
a normal, undamaged eye. Differences in amplitude of the a- and b- waves between the 
operated eye and the contralateral eye were calculated and analyzed. As a positive 
control, other rats (n = 8) were injected intravitreally with N-methyl-D-aspartate (2 ul of 
lOmM NMDA), which reduces the amplitude of both a- and b-waves, and ERG's were 
on 
obtained 2 weeks later as described above . 
Histology was performed on_Operated and contralateral control eyes, which were 
enucleated and fixed in 10% phosphate buffered formalin (Fisher Scientific, Fair Lawn, 
NJ) for at least 1 week. 
Glaucomatous changes in the fundus were observed by slit-lamp examination on 
anesthetized rats. Retinal images were recorded with a 3.2 mega pixel digital camera 
(PowerShot SI IS, Cannon, Tokyo, Japan) retrofitted to a slit lamp (Zeiss, Germany). 
Full resolution images were obtained with a constant optical zoom (10 X) and processed 
with Metamorph™ image analysis software. Cup to disc ratios were obtained for area, 
height, and width using Metamorph™ image analysis. For area measurements, the outer 
edge of the cup and disc were selected, pixels were counted, and the cup to disc ratio was 
determined. For individual height and width cup to disc measurements, diameters for 
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each was obtained through a central plane. The ratios were then expressed as the cup 
diameter to the outer disc diameter. 
A standard tail cuff apparatus was used to measure heart rate (HR) and blood 
pressure (BP) on sedated rats. A pulse amplifier (Model 29, IITC, Woodland Hills, CA) 
was placed in line for digital data conversion. Data were processed with a DasyLab 
generated analysis module. 
Student's t-test was used to compare data from RGC cell counts, treatment with 
timolol, and changes in the HR, BP and ERG amplitude. A one-way ANOVA analysis 
was performed to compare IOP, heart rate and blood pressure over time between strains. 
Other statistical tests are specified in the results section. A difference ofp < 0.05 was 
considered statistically significant. All values reported as mean ± SD unless otherwise 
noted. 
Results 
Development of Ocular Hypertension 
Ocular hypertension was achieved by ligating two superior (temporal and nasal) 
and one inferior temporal vortex veins. Ligation of all four vessels resulted in pan 
vascular rupture in the anterior chamber and was not desirable. No differences were 
noted when the position of the ligatures was changed, for e.g. two inferior (temporal and 
nasal) and one superior (temporal or nasal) (data not shown). However, the superior 
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nasal vessel was preferred over the inferior nasal due to the presence of the nictitating 
membrane in this aspect and also because of its ease of access. The primary outcome 
measure for ocular hypertension was a consistent difference of at least 5 mm Hg between 
the operated eye and the normal contralateral eye. In all strains of rats, this benchmark 
was achieved between 1 and 4 weeks following surgery. In the week following surgery, 
post-surgical inflammation was occasionally noted, which resolved after treatment with 
topical antibiotics and steroids. No signs or symptoms of inflammation persisted beyond 
one week. Animals were removed from the study only due to failure to meet 
hypertensive criteria for more than two consecutive weeks or to adverse effects of 
sedation. 
Sprague Dawley Rats 
Sprague Dawley rats developed ocular hypertension within one week of surgery 
(Figure 5). Although the contralateral control was elevated at one week, it returned to 
baseline measurement by two weeks and remained constant throughout the study period. 
At two weeks, IOP in the operated eye was significantly elevated to 17.0 ±2.1 mmHg 
from a baseline of 9.6 ± 0.6 mmHg. In the initial group (n=5), all rats developed ocular 
hypertension and remained elevated past 6 weeks. This surgery was repeated in another 
group (n=9) with a total of 14 rats, out of which only one was removed from the study 
due to failure to meet the hypertensive criteria for two consecutive weeks. Ocular 
hypertension in Sprague Dawley rats remained for 40 wks. In sham-operated animals 
(n=4), IOP remained at baseline value of 11.0 ± 1.2 mmHg to 11.3 ± 1.0 mmHg four 






Figure 5: Vortex vein ligation in Sprague Dawley rats. 
Week 0 represents baseline presurgical IOP. By 2 weeks after surgery IOP, measured 
with Goldmann tonometer, was significantly elevated (p<0.05, n=13). IOP remained 
significantly elevated over 40 weeks (p<0.05) maintaining a >5 mm Hg increase over the 
contralateral control eye. All controls used in this experiment were unoperated 
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Figure 6: Vortex Vein ligation in Brown Norway rats. 
IOP was significantly elevated in operated eyes by 3 weeks following surgery (p<0.05, 
n=4). However after 15 weeks IOP gradually decreased and no significant IOP elevation 
was seen after 34 weeks in the operated eye compared to contralateral control eye. All 
pair wise comparisons conducted using Student's t-test. 
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Weeks 
Figure 7: Vortex vein ligation in Long Evans rats. 
Long Evans rats showed a rapid response to episcleral vein ligation as IOP was 
significantly elevated by 1 week (p<0.05, n=5). Operated eyes maintained a > 5 mm Hg 
increase over contralateral control eyes for 6 weeks (p<0.05). However, measurements 
were suspended after 6 weeks due to persistent, rapidly progressing conjunctival 
vascularization. All pair wise comparisons conducted using Student's t-test. 
Brown Norway Rats 
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Three weeks following surgery, IOP was significantly elevated in Brown Norway 
rats to 10.5±1.8 mmHg from a baseline of 6.8±0.1 mmHg (Figure 6, n=4). Peak IOP at 
15 weeks was 16.1±1.3 mmHg but was not maintained afterwards. Fifteen weeks after 
surgery, one rat failed to meet the inclusive criteria and by 35 weeks none met the 
hypertensive criteria. No significant anatomical differences were seen in Brown Norway 
rats as veins were easily located lateral to the rectus muscles and were similar in size and 
shape to the Sprague Dawley rats. 
Long Evans Rats 
In Long Evans rats, ocular hypertension developed within one week (Figure 7, n = 
5). By 3 weeks one rat failed to meet the criteria for ocular hypertension. While all Long 
Evans rats developed ocular hypertension, IOP remained elevated for only 6 weeks. Of 
particular note was the development of rapidly progressing conjunctival vascularization, 
even when subjected to minimal surgical manipulation. Within 6 weeks, this 
vascularization had extended to the limbus resulting in the termination of the study. 
Wistar Rats 
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Vortex vein ligation in Wistar rats was met with several surgical complications. 
Significant anatomical differences, mainly, their smaller sized globes and difficulty in 
locating the vortex veins contributed to these failures. Due to these reasons the surgical 
procedure was slightly modified to include cauterization of the veins. Even after this 
modification, the change in IOP did not meet the criteria for ocular hypertension and was 
inconsistent and short-lived. After one week IOP increased from 10.5±1.7 mmHg to only 
11.5±0.7 mmHg. By week 4, IOP was 13.1±3.2 mmHg in two rats. However, all rats 
gradually succumbed to sedation related respiratory complications and died within 6 
weeks. During autopsy, numerous collateral arteries bypassing the ligation were noted. 
Heart rate and blood pressure 
Heart rate and blood pressure were measured in each strain of rats before 
surgery (e.g. baseline) and in the weeks following surgery. Four weeks after surgery, 
heart rate and blood pressure were unchanged from the presurgical baseline with one 
exception (Table 3). Systolic blood pressure was significantly increased in the Long 
Evans rats and diastolic pressure tended to decrease. There were differences between the 
strains, but they were strain specific since these differences were reflected in baseline 
data. For example, presurgical heart rate in Long Evans rats was significantly higher than 
in the other three strains. 
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Heart rate and blood pressure remained constant for each strain for the 
duration of the experiment; preop values were not obtained on all rats. 
Postop = 4 weeks after surgery in the presence of elevated IOP 
f significantly different from other strainsp < 0.05. 
% significantly different from baseline,/) < 0.05. 
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Electroretinogram (ERG) 
Sprague Dawley rats with sustained ocular hypertension were examined by ERG 
and fundus photography to ascertain whether the sustained increase in IOP resulted in 
glaucomatous changes to the retina. ERG's were performed on both eyes at terminal 
points (32 - 72 weeks). The amplitudes of the a-wave and b-wave in the hypertensive eye 
were compared with the contralateral normotensive eye. While no ERG aberrations were 
seen up to 12 weeks, after 30 weeks the a-wave amplitude significantly decreased by 
45.9±22 % (p = 0.03) and the b-wave by 34.9±24% (p < 0.03) from that measured in the 
normotensive contralateral eye (n=13). Statistical analysis revealed close correlations 
between the amplitudes of the a- and b-waves with both IOP and retinal ganglionic cell 
loss (Table 4). 
In normal rats, injection of NMD A diminished the amplitude of both a- and fa-
waves in a manner similar to the surgically ligated eyes. Two weeks after injection, the a-
wave amplitude significantly decreased to 55±0.6% (p < 0.002) of the preinjection 
amplitude. Concomitantly, the b-wave amplitude decreased to 49±0.8% (n=8, p = 0.02). 
The ERG wave amplitude in the contralateral control eye did not deviate significantly 
throughout the observation period (p<0.521). 
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Representative retinas from Sprague Dawley rats with sustained ocular 
hypertension were analyzed for morphological changes. The retinal cell counts were 
obtained from retinal cross-sections at the optic nerve level. Three of 14 ligated eyes 
with sustained IOP elevation were sectioned. While the overall retinal thickness 
remained constant in the ligated and control eyes, reduction in density of the inner and 
outer plexiform layers, and the retinal ganglionic layers was noted in the ligated eyes. 
Retinal ganglionic layer cell density was significantly reduced to 46.5 ±3.9 (cells per 
200um) compared to 62.5 ± 4.5 in the contralateral control, a 26% reduction (p<0.05). A 
significant correlation between increased IOP and RGC loss was noted (r2 = 0.946, p = 
0.05). Further, the ganglionic cell layer (GCL) appeared to be disrupted in the ligated 
eyes (Figure 8a) compared with the contralateral (control) eye, where all the retinal layers 
were intact (Figure 8b). In retinal cross-sections, significant cupping was observed in 3 
of 4 ligated eyes (Figure 9a) compared to the contralateral control (Figure 9b). Also, 
enlargement of choroidal vessels was noted in all ligated eyes analyzed (Figure 10a) 
compared to the contralateral control (Figure 10b). No iris synechia or profound angle 
closure was seen in hypertensive eyes. 
Figure 8A 
Figure 8B: 
Figure 8: Representative retinal cross sections of ligated and contralateral control eyes at 
the level of the optic nerve. 
All sections were digitally photographed at 20X magnification. GCL - ganglionic cell 
layer, IPL - inner plexiform layer, INL - inner nuclear layer, OPL - outer plexiform 




Figure 9: Retinal cross-sections representing cupping of the optic disk. 
A. Cupping in the ligated eye. B. No cupping in the contralateral control eye. 
Histological analysis was performed 32-72 weeks after ligation surgery. All 




Figure 10: Anterior segment analysis of Sprague Dawley rats that have maintained IOP 
elevation past 32 weeks. 
Although no iris synechia or profound angle closure was observed, significant choroidal 
vessel dilation was present in ligated eyes (A) indicated by arrow, compared to normal 
vasculature in the contralateral control (B) indicated by arrow. 
Fundus Examination 
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Pathologic changes in retinal structure were evident in the Sprague Dawley group. 
Within 30 weeks after surgery, there was a greater than 35% increase in optic cup area of 
the hypertensive eye compared with contralateral normal eye. There was also a 14% 
increase in cup to disc ratios as measured by both width and height. The cup to disc 
ratios for both width and height increased to 0.65±0.045 and 0.66±0.045, respectively in 
the operated eye when compared to 0.57±0.07 width and 0.58 ±0.06 height in the control 
eye (p<0.05). The optic disc of the operated eye remained circular determined by a 
width to height disc diameter ratio of 1.01. A decrease in retinal vasculature was also 
apparent. A significant correlation was noted between IOP and cup to disk ratios for 
width (r2 = 0.908,/? < 0.05) and height (r2 = 0.901,/? < 0.05). By comparison, fundus 
examination of the contralateral eye was normal. The optic disc was circular as 
determined by the width to height disc diameter ratio of 1.01. There was no substantial 
cupping. 
Corresponding changes were not observed in the Long Evans or Wistar rats where 
the duration of increased IOP was less than six weeks. Due to their pigmentation, the 
optic disc margin was not easily demarcated in Brown Norway rats. However, 14 weeks 
after surgery, the morphology of optic disc and retinal vessels had not changed from their 
presurgical appearance. 
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Response to timolol 
To ascertain if the operated eyes respond to standard antihypertensive therapy, a 
single dose (20 |il) of timolol 0.5% was administered to the hypertensive eye. IOP was 
measured every 30 minutes over a 2 hr period (Figure 11). Within 0.5 hr, in Sprague 
Dawley rats timolol significantly decreased IOP from baseline and it remained 
significantly decreased for over 2 hr (p<0.05). Timolol decreased the IOP to the extent 
that it was no longer different than that of the contralateral eye (p= 0.77). In Brown 
Norway rats IOP initially decreased from pretreatment values (p<0.05), but the IOP 
remained greater than that in the contralateral eye (p < 0.01). Long Evans rats had the 
least response to timolol treatment. At 0.5 hr, there was only a 2 mmHg difference 
between eyes, and IOP remained significantly higher than in the contralateral eye (p < 
0.01). No drug crossover IOP effects were observed in contralateral eyes of any strain 
throughout the study period. 
Discussion 
As new pharmacologic approaches for treatment of glaucoma emerge, 
demonstration of efficacy and comparison with current therapy requires suitable 
preclinical models. Although the specific etiology of primary glaucoma is not well 
understood, increased resistance to aqueous humor outflow from the eye causes IOP to 
increase. As ocular hypertension remains a primary risk factor, most models use an 
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Figure 11: Effects of timolol (0.5%, 20ul) on IOP were measured over a 2 hr period in 
three rat strains with surgically elevated IOP. 
Sprague Dawley rats responded rapidly with a significant decrease at 0.5 hr and lasting 2 
hr (p<0.05). The response of Brown Norway rats was moderate with a significant 
decrease only at 0.5 hr and 1 hr (p<0.05). Long Evans rats had small but not significant 
decrease in IOP. All data are mean ± SD (n=4/group), all comparisons conducted by 
ANOVA analysis. Data at 0 hr represent baseline values before administration of timolol. 
* Significant compared to baseline, p<0.05 
Both surgical and nonsurgical approaches have focused on increasing resistance to 
aqueous humor outflow. When hyaluronic acid was injected intracamerally in Wistar rats, 
IOP increased, but only for 8 days; multiple injections were required to sustain the 
increase m . Karim et al elevated IOP by argon irradiation of rat trabecular meshwork in 
Wistar rats120. Also, Levkovitch-Verbin et al used a diode laser aimed at the trabecular 
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meshwork and vortex veins which raised IOP in Wistar rats for 9 weeks 
With only moderate success of the nonsurgical approaches to sustain ocular 
hypertension, surgical intervention has been more successful. After cauterization of 3 
vortex veins and 2 episcleral veins in Brown Norway rats, only 36% developed elevated 
* 10A 
IOP with duration of 5 weeks . Cauterization of 3 episcleral veins increased IOP 1.6 
fold over control in Wistar rats, but required re-cauterization after 6 months 122. In our 
study, compared to cauterization, minimally invasive vortex vein ligation resulted in 
significant IOP elevation that lasted at least a year. In addition, the success rate for 
developing elevated IOP was higher (-90% for Sprague Dawley rats). Therefore, 
ligature of the vortex veins yields in a consistent and longer lasting ocular hypertension. 
The development of our surgical technique to achieve a sustained elevation of 
IOP required several iterations. Unfortunately, complete dissection to expose the vortex 
vessels caused anterior segment ischemia manifested as erythema, corneal opacification 
and central ulceration that did not improve with tarsorrhaphy and antibiotics. Ocular 
hypotension frequently occurred, probably due to disruption of perfusion to the iris 
major arterial circle, as well as aqueous humor production by the ciliary body. This 
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response is analogous with the anterior segment ischemia that occurs in patients after 
strabismus surgery when multiple rectus muscles are disinserted. 
These unsatisfactory surgical results prompted us to develop a technique, in which 
careful attention was given to minimizing surgical trauma, primarily by identifying the 
vortex vessels directly through the conjunctiva and then ligating them using only very 
small minimal incisions. We hypothesized that the greater the surgical insult, the faster 
and more extensive the development of collateral circulation. It was crucial that incisions 
of the conjunctiva be limited to the immediate area of the vortex veins. Ligation rather 
than cautery of vortex veins is essential. Collateral circulation was more extensive when 
cautery alone or cautery following ligation was used. It is possible that the use of cautery 
alone is a sufficient local insult to stimulate the formation of collaterals. Similarly, in 
other studies where only cautery was used, the duration of ocular hypertension was 
shorter than that following vortex vein ligation '. 
Following ligation of three of the four vortex veins, a steady elevation was 
achieved without negative impact on other ocular structures except for the retina. All 
possible ligation combinations were attempted, but superior (nasal and temporal) and 
inferior temporal vessels were most commonly ligated due to their ease of access. The 
inferior nasal vein was most difficult to access and caused excessive damage to 
surrounding tissues during ligation. Ligation of all four vortex veins resulted in infarcted 
blood vessels due to almost complete occlusion of the outflow facility. Excessive 
occlusion of the outflow apparatus and stimulation of angiogenic factors promotes 
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formation of anastomoses or collateral circulation 127'128. This stimulus is amplified by 
surgical trauma; in our study the surgical trauma was limited to the immediate area of the 
vortex veins to preserve much of the normal anatomy of the eye. These novel 
modifications in the surgical procedure improved the performance of the ocular 
hypertension model. Using a similar technique, Yu et al reported an IOP elevation of 
approximately 9 mmHg in Wistar rats over the control eye that was compromised by 
collateral formation in 60% of the cases 126. Subsequently, repeated ligations were 
necessary to maintain the IOP elevation reported to be maintained over a 7 month period. 
Although the increase in IOP was of similar magnitude in Long Evans and Brown 
Norway rats, these strains are less suitable models than the Sprague Dawley rats. In both 
Long Evans and Brown Norway rats, the elevated IOP was not sustained and optic nerve 
damage minimal. Rapid formation of anastomoses and postoperative complications 
further compromised the Long Evans rat model. The Long Evans rats did not respond to 
timolol and the response in the Brown Norway rats was small and of short duration. In 
both strains morbidity associated with sedation was high. If increased IOP could be 
sustained, Brown Norway rats have potential as a model due to the ease of observing 
changes in retinal and optic nerve morphology. Preliminary studies with Wistar rats were 
similarly unproductive. Wide variations in vortex vein anatomy and sedation-related 
morbidity precluded inclusion of a suitable number of animals. 
It was not surprising that the responses varied between the rat strains because 
there are considerable differences in the biochemical, pharmacological and neuronal 
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responses among rat strains ' . Although rats in these experiments were sex and age 
matched, certain differences, such as response to anesthesia and surgery, persisted. Strain 
dependent neovascularization and development of collateral circulation could be 
attributed to innate regulators of vascularization. Compared to Sprague Dawley rats, 
retinal ischemia in Brown Norway rats produces substantially more VEGF . Nitric 
oxide synthetase and glutamate activity is strain dependent, which may have important 
implications for the extent of glaucomatous retinal damage developed in different strains 
132. Brown Norway rats also have impaired autoregulation of blood pressure compared to 
Long Evans or Sprague Dawley rats, which may explain their poor response to beta-
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adrenergic blockade . If blood pressure in Brown Norway rats does not respond 
normally, regulation of IOP may also be atypical, since diurnal variation in IOP 
correlates directly with diurnal variations in blood pressure 134. 
Additionally, this technique was also performed on New Zealand White rabbits 
(data not shown). Ligation of three vortex veins failed to elevate IOP, while ligation of 
all four caused excessive IOP elevation and rupture of veins. In ligated rabbits (three 
vein), development of significant collateral circulation was noted (Figure 12) which could 
contribute to lack of IOP elevation. Therefore, it can be concluded that this strain of 
rabbits is not suited for this technique as they have a greater potential to develop 
collateral circulation. 
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Figure 12: Vortex vein ligation surgery performed on New Zealand White Rabbits. 
No IOP elevation was produced in the operated eyes due to significant collateral vessel 
formation within 2 weeks of surgery. 
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Once the effectiveness in maintaining ocular hypertension was established, we 
examined whether this model mimicked other salient factors associated with glaucoma. 
In our model significant loss of both a- and b- wave amplitudes were noted 32 weeks 
after surgery. The loss of retinal ganglionic cells and diminished amplitude of ERG wave 
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pattern is synonymous with glaucomatous damage . While a-wave changes are 
pathognomic, the decrease in b-wave amplitudes raise concerns of possible ischemic 
involvement and choroidal hypertension in the ensuing retinal damage. With any 
occlusive surgical procedure, a potential for ischemic damage exists. With vortex vein 
ligation, dilation of choroidal vessels leads to IOP elevation that is gradual and prolonged 
and does not directly affect central vessels of the eye. Therefore any resulting ischemic 
insult is not as severe in comparison to damage induced by ligature of optic vessels 
B-wave deficits are also observed in DBA/2NNia mice model of angle closure glaucoma 
136. In this genetic model both a- and b-wave amplitudes decreased after 8 months, thus 
sharing many similarities with human glaucoma, however the specific causes of the ERG 
changes in DBA/2NNia mice is not clear. Following other procedures, such as injection 
of ICG dye in the anterior chamber with a rapid onset of ocular hypertension, it would be 
expected that ischemic injury would be a major contributor to retinal damage. In these 
models, b-wave damage is prominent in comparison to the inner retinal function 124. In 
all cases, the glaucomatous condition presents with both a- and b-wave deficits and 
contributions by ischemia and choroidal hypertension cannot be ruled out. In addition to 
the significant retinal functional damage, pathologic structural changes were observed in 
retinal vasculature and the optic disc. Although all measured parameters (area, height 
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and width) of the cup and disc increased in the operated eye, the disc remained circular, 
indicative of early glaucomatous changes. 
The results of the present study help to define optimal conditions to create an 
effective rat ocular hypertensive model. While IOP increased gradually in most strains, 
only in Sprague Dawley rats was it sustained for up to a year. Retinal degeneration was 
coincident with the sustained increase in IOP. The Sprague Dawley rat model was also 
remarkably free of postoperative complications and responded well to standard 
pharmacotherapy with timolol. Indeed, we have recently used this Sprague Dawley 
model to demonstrate that repeated topical administration of the cannabinoid agonist 
WIN-55-212-2 significantly decreased IOP without developing tolerance 90. In 
conclusion, the results of the present study indicate that ligation of three of four vortex 
veins in the Sprague Dawley rat is an optimal preclinical rat model to investigate 
pharmacological treatments for intraocular hypertension. 
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CHAPTER VI 
OCULAR PHARMACOKINETICS OF 0-1812 AND 0-2545 IN AN 
ARTIFICIALLY PERFUSED RAT EYE 
Introduction 
A major interest in ocular pharmacology has been the description and 
improvement of therapeutic drug absorption in the compartments of the eye. One of the 
primary factors affecting a drug's pharmacokinetic profile is its lipophilicity. It is well 
known that lipophilic compounds can more easily cross biologic membranes, and thus, 
can more easily reach their sites of action. Cannabinoids are inherently lipophilic, 
especially 0-1812. Lipophilic compounds are difficult to solubilize and to dissolve 
frequently require solvents like ethanol and DMSO. Moreover, lipophilic compounds 
tend to precipitate out of solution and have a limited shelf life. 
While hydrophilic compounds would be safer to administer, their absorption 
profiles must be comparable to that of lipophilic compounds. Measurements of 
intraocular drug concentrations over time are limited, however, by the amount of aqueous 
or vitreous samples that can be obtained. 
A relatively new method for the elucidation of pharmacokinetic profiles in vivo is 
microdialysis. It has been successfully utilized for regional sampling of low-volume 
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compartments of many tissues, such as the brain, joints, kidney, and eye . By taking a 
minute amount of aqueous humor and re-perfusing an equivalent volume, microdialysis 
sampling allows for serial measurements of the aqueous fluid in order to create a 
complete concentration versus time curve for an individual subject. Rittenhouse et al 
used microdialysis sampling to produce intra- and inter-animal absorption profiles of 
propranolol after topical and intracameral injection, showing it to be an accurate and 
easily reproducible method . In this study, we will use a similar method to examine the 




Male rats weighing ~ 200 gm (14 Sprague Dawley, 4 brown Norway, 59 Long 
Evans and 5 Wistar) underwent vortex vein ligation. All studies were conducted in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research, and were approved by the Eastern Virginia Medical School (EVMS) 
Institutional Animal Care and Use Committees. 
Surgical Model 
An adult male Sprague Dawley (SD) rat was euthanized by IP injection of Fatal 
Plus in accordance with IACUC (Institutional Animal Care and Use Committee) 
regulations. Placed in supine position, Y incision was made to expose chest cavity. Once 
descending aorta was exposed and isolated, the inferior aorta was sutured closed, 
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superiorly to the suture but inferior to the aortic arch. A window into the lumen of the 
aorta was made and tubing placed securely inside; held with a suture and surgical glue. 
At the end proximal to the heart, the ascending aorta was sutured closed. Once a closed 
system was achieved, profusion began and maintained IOP during cannulation without 
elevation of IOP. Modified 27 gauge needle accompanied by the cannulation apparatus 
was inserted into the OS anterior chamber. OD received the same insertion technique 
using the 27 gauge needle into the OD vitreous chamber. Perfusion with IX PBS was 
maintained for a period with stability, topical drug was added and samples taken every 10 
minutes for 2 hours for analysis by HPLC. 
Cannabinoid concentration was quantified by HPLC. Using a modification of the 
method described by Barberi-Heyob and colleagues, dialyzed aliquots were injected on a 
5-um reverse-phase column (Prodigy 5 um ODS(2) analytical column, 150 x 4.6 mm, 
Phenomenex, Torrance, CA) at ambient temperature with a mobile phase of acidified 
acetonitrile water (pH = 4.0) solution94'95. The flow rate was 1 mL/min with UV 
detection (254 nm). Chromatograms were analyzed using Beckman System Gold 
software (Beckman Instruments, Inc., Fullerton, CA). 
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Figure 13: Pharmacokinetic profile of 0-1812 and 0-2545 in the anterior chamber of an 
artificially perfused rat eye. 
Eyes were dialyzed for 120 min with a sample taken every 10 min. 
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Results 
Lipid soluble 0-1812 more effectively penetrates the anterior chamber 
Cannabinoid concentration as a result of topical administration was assessed in 
the anterior chamber of a rat eye (Figure 13). After artificial perfusion, dialysates were 
collected every 10 min and analyzed with an HPLC. Both 0-1812 and 0-2545 rapidly 
crossed through the cornea into the anterior chamber of the eye. Lipid soluble 0-1812 
was more effective than water soluble 0-2545 in penetrating the anterior chamber, a 
difference of 2 nM was noted (n=l for each drug). Cannabinoid concentration decreased 
over time. After 80 min, there was no trace of 0-2545; however 0-1812 concentration 
was greater than 2 nM for 120 min. 
Lipid soluble Q-1812 more effectively penetrates the posterior chamber 
Cannabinoid concentration after topical administration was assessed in the 
posterior chamber of a rat eye (figure 14). Cannabinoid transport to the posterior 
chamber was not as rapid as compared to the anterior chamber. Concentration of 0-1812 
in the posterior chamber was 5 nM after 30 min and decreased to 2 nM after 90 min 
where it remained for the duration of the study (120 min). In contrast, maximal 
concentration of 0-2545 was 3 nM after 30 min, but was eliminated after 80 min. After a 
single topical dose of 0-1812 or 0-2545, lipid soluble 0-1812 more effectively 
penetrated the posterior chamber than water soluble 0-2545. 
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Figure 14: Pharmacokinetic profile of 0-1812 and 0-2545 in the posterior chamber of 
an artificially perfused rat eye. 
Eyes were dialyzed for 120 min with a sample taken every 10 min. 
Discussion 
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Compared to other tissues, the aqueous and vitreous chambers are relatively 
privileged sites. Compared with systemic administration, where drug plasma 
concentration is often sufficient to obtain therapeutic levels in a given region, it is 
difficult to do so in the eye because certain drugs do not cross the blood-vitreous barrier 
137. However, certain substances are more suited than others to cross the blood-vitreous 
barrier, namely, lipophilic compounds. Mayers et al compared the intraocular 
concentrations of lipophilic chloramphenicol versus hydrophilic amikacin after 
intravenous administration . They demonstrated that chloramphenicol reached higher 
concentrations in the anterior chamber than did amikacin. Moreover, chloramphenicol 
had a rate of elimination from the aqueous humor identical to its rate of elimination from 
the serum, while amikacin had a lower peak aqueous concentration and was more quickly 
eliminated. 
Lipophilic drugs can reach therapeutic levels in the eye when administered 
intravenously, although high doses are required. Mayers et al found that, when directly 
injected into the eye, chloramphenicol and amikacin were both eliminated more quickly, 
and the two compounds had comparable half-lives 138. They attributed this to the lack of 
a membranous barrier to the drainage mechanism of Schlemm's canal, which abolishes 
the lipophilic compound's absorptive advantage. While intravitreal injection might hold 
promise for improved concentration curves of hydrophilic compounds, it is not a 
clinically desirable option due to patient discomfort, anxiety, and increased risk of 
infection. 
80 
The ideal mode of administration of ocular medication is topically. Drops can be 
applied easily by the patient in almost any setting. Studies have shown, however, that 
topically-administered drugs achieve much lower concentrations than those injected 
intraocularly93. To evaluate how the concentrations of these drugs affect their action, an 
accurate description must be made of its pharmacokinetic profile. This can be done in a 
number of ways. One method is to take serial samples of aqueous humor from the same 
subject. The volume of fluid available for sampling is limited, however. While this 
might be overcome by a "washout" period in between treatments to replenish aqueous 
fluid and clear the experimental compound, repeated cannulation of the sclera could lead 
to inflammation and scar tissue formation, which would affect sampling. Another 
technique involves taking samples of fluid from a large number of subjects at staggered 
time intervals after administration of the experimental compound and combining all the 
data into one concentration vs. time curve. This can be skewed by variability between 
individual subjects, however. 
Several methods have been employed to accurately model concentration curves in 
the eye. Drusano et al attempted to create a reliable curve of plasma concentrations vs. 
vitreous concentrations of ciprofloxacin using single measurements of intraocular 
concentrations from multiple subjects and a population pharmacokinetic modeling 
program 137. While this allows for fewer vitreous samplings, repeated plasma samplings 
are required; furthermore, it is based on data compiled from different subjects which may 
be skewed by inter-subject variation. Mayers et al utilized a method consisting of 
multiple paracenteses to observe the absorption of antibiotics 138. By beginning to sample 
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from different subjects at different time intervals, they showed that the number of 
samples taken do not affect clearance of the drug from the aqueous humor. This method 
required many subjects, however, and did not rule out the possibility of an occult 
inflammatory process affecting the clearance of the antibiotics. 
Using in vivo microdialysis, a pharmacokinetics of lipid and water soluble 
cannabinoids can be made with continuous sampling. Since these cannabinoids are 
newly synthesized, their pharmacokinetic profiles have not been elucidated. After a 
single topical administration, lipid-soluble 0-1812 effectively penetrated both the 
anterior and posterior chamber and was maintained for at least 120 min. 0-2545, being 
water-soluble, did penetrate both the ocular chambers, but was eliminated more rapidly 
than the lipid soluble 0-1812. 
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CHAPTER VII 
TOPICAL APPLICATIONS OF NOVEL CANNABINOIDS, 0-1812 
AND 0-2545, REDUCED INTRAOCULAR PRESSURE IN A RAT 
OCULAR HYPERTENSIVE MODEL 
Introduction 
IOP is the most important risk factor for the development of glaucoma, a leading 
cause of blindness world wide 21'139'140. Consequently, the reduction of IOP is recognized 
as the main treatment to reduce visual loss in glaucoma patients. Several multicenter 
clinical trials have demonstrated that reducing IOP retards the progressive visual field 
damage in patients with primary open angle glaucoma or normal tension glaucoma *'36. 
A variety of naturally occurring and synthetic cannabinoid agonists have been 
evaluated for their ability to reduce IOP in humans and laboratory animals 14M43. Most 
bind both cannabinoid receptors, the CB1 receptors which are predominantly localized in 
the CNS 63 and the CB2 receptors identified in the periphery and associated with immune 
function 144. It has been suggested that the IOP reducing effects of cannabinoid agonists 
are related to their actions on the CB1 receptor, whose presence has been demonstrated in 
the ciliary body, iris, trabecular meshwork, and retina 13'16>44,52. Stimulation of these CB1 
receptors is hypothesized to decrease IOP and, consequently, may retard the progression 
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of glaucoma. Recently, CB2 receptors in the trabecular meshwork have also been 
c-i 
implicated in cannabinoid-mediated IOP reduction . 
The therapeutic usefulness of systemic cannabinoids is limited by their well-
described psychomimetic and systemic effects; however, topical drug delivery may 
reduce these problems. The primary purpose of the present study is to determine whether 
acute topical administration of 0-1812, 0-2545 is comparable to WIN 55212-2, a well 
studied high efficacy aminoalkylindole cannabinoid analog. With topical application, 
undesired systemic and ocular effects can be obviated while maintaining efficacy. The 
efficacy of 0-1812, 0-2545, and WIN 55212-2 was evaluated in rats with high IOP, 
following surgical occlusion of three vortex veins. As an additional measure, receptor 
(CB1 or CB2) dependency of the IOP effect in a rat chronic ocular hypertensive model 
was studied by using selective antagonists, SR 141716A or SR 144528, for each 
respective cannabinoid receptor. 
Experimental Design 
Sprague Dawley rats were randomly assigned to either 0-1812, 0-2545, WIN 
55212-2, or Tocrisolve™ (vehicle) treatment groups. Only 0-1812 and WIN 55212-2 
were dissolved in Tocrisolve™ while 0-2545 was water soluble and dissolved in PBS. 
These compounds were applied topically to the hypertensive right eye. The vehicle 
served as the negative control while WIN 55212-2 was a positive control. All animals 
were allowed a minimum washout period of 1 wk between subsequent experiments. The 
left eye (OS) served as the untreated control. At the beginning of each experiment, 
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baseline IOP, heart rate (HR), and blood pressure (BP) measurements were obtained. IOP 
measurements were repeated at 30, 60 and 120 min after drug administration, in the 
treated eye (OD), as well as in the contralateral untreated eye (OS). HR and BP were 
also measured at 30, 60 and 120 min after drug administration. Before and at the 
conclusion of each experiment, all eyes were examined by slit lamp for signs of ocular 
irritation and by in vivo confocal microscopy for changes in corneal thickness. 
Experiments using CB1 antagonist, SR141716, or CB2 antagonist, SR 144528, 
were performed to determine receptor specificity of these compounds. The CB 
antagonists were prepared by dissolving 50 ug of compound in 50 ul of Tocrisolve™ 
(0.1%). To get maximal effect, the antagonists were applied topically 30 min prior to the 
administration of the cannabinoids. The CB1 antagonist was SR141716 (Ki [CB1] = 5.6 
nM, Ki [CB2] >1000 nM) I45 and the CB2 antagonist was SR 144528 (Ki [CB2] = 0.6 
nM,Ki[CBl] = 437nM)146. 
Additional experiments to test for the confounding effects of sedation on IOP 
were performed. In this experiment, animals were sedated (ketamine 40 mg/kg and 
acepromazine 6 mg/kg) and IOP measured at 0, 30, 60 and 120 min in both operated and 
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Figure 15: Dose response to topically applied 0-1812 in surgically hypertensive eyes. 
The baseline IOP (t=0) was 16.0 ±0.9 mmHg. N = 10 rats/group. 
* Significantly reduced when compared to baseline,/? < 0.05. 
f Significantly reduced when compared to vehicle, p<0.05. 
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Results 
Effects of topically applied 0-1812 
At baseline (t=0), the IOP for the operated eye (OD) was 16.0 ±0.9 mm Hg and 
for the contralateral (non-operated) eye was 10.1 ± 0.5 mm Hg. Following a single 
topical application of 0-1812 (1.0, 0.1 and 0.01%) or vehicle alone to the operated eye, 
the change in IOP (mm Hg) from baseline was measured for up to 120 min (Figure 15). 
After 30 min, all concentrations of 0-1812 significantly decreased IOP (p 
<0.001) from 30 to 120 min. Maximal effect was observed at 60 min for all 
concentrations. At this time period, 1.0 % elicited a significantly greater IOP reduction 
than either 0.1 or 0.01% concentrations (p<0.001). At the end of the study period (120 
min), only 1.0% and 0.1% treatment continued to maintain IOP reduction while for the 
0.01% concentration IOP had already returned to baseline. Thus, magnitude and duration 
of effect was dose dependent. Tocrisolve™ (vehicle) alone had no effect on IOP 
(p>0.08). No crossover effects were seen in the contralateral eyes. 
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Figure 16: Dose response to topically applied 0-2545 in surgically hypertensive eyes. 
The baseline IOP (t=0) was 16.0 ±0.9 mniHg. N = 7 rats/group. 
* Significantly reduced when compared to baseline,/? < 0.05. 
f Significantly reduced when compared to vehicle, p<0.05. 
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Effects of topically applied 0-2545 
At baseline (t=0), the IOP for the operated eye (OD) was 16.0 ±0.9 mm Hg and 
for the contralateral (non-operated) eye was 10.1 ± 0.5 mm Hg. Following a single 
topical application of 0-2545 (1.0 and 0.1%) or vehicle alone to the operated eye, the 
change in IOP (mm Hg) from baseline was measured for up to 120 min (Figure 16). 
After 30 min, both concentrations of 0-2545 significantly decreased IOP (p 
<0.03, n=7) for up to 120 min. Maximal effect on IOP was observed 60 min after 
administration of 0-2545. The IOP reduction was similar for both 1.0 and 0.1% 
concentrations throughout the study period. At the end of the study period (120 min), 
although IOP remained significantly reduced from baseline, both 1.0 and 0.1% treatments 
had already started to return toward baseline (p < 0.05, n=7). There was no effect of 
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Figure 17: Topically applied WIN55212-2 in surgically hypertensive eyes. 
The baseline IOP (t=0) was 16.0 ±0.9 mmHg. N = 10 rats/group. 
* Significantly reduced when compared to baseline,/? < 0.05. 
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Effects of topically applied WIN55212-2 
At baseline (t=0), the IOP for the operated eye (OD) was 16.0 ±0.9 mm Hg and 
for the contralateral (non-operated) eye was 10.1 ± 0.5 mm Hg. Following a single 
topical application of WIN55212-2 (1.0, 0.25, 0.06, and 0.015%) or vehicle alone to the 
operated eye, the change in IOP (mm Hg) from baseline was measured for up to 120 min 
(Figure 17). 
By 30 min, all concentrations of WIN55212-2 significantly decreased IOP (p 
<0.001) from 30 to 120 min, except for WIN55212-2 0.015% (p = 0.59, n=10). 
WIN55212-2 1.0, 0.25 and 0.06% also significantly reduced IOP compared to 0.015% 
concentration 30 min after administration (p=0.03). Maximal effect on IOP was observed 
60 min after administration of WIN55212-2. At this time period, both 1.0 and 0.25% 
elicited a significantly greater IOP reduction than 0.06 and 0.015% concentrations 
(p<0.001). At the end of the study period (120 min), only 1.0% treatment continued to 
maintain IOP reduction while 0.25 and 0.06% concentrations had already started to return 
toward baseline. The magnitude and duration of effect was dose dependent. Vehicle 
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Figure 18: Topical administration of WIN55212-2 in the operated eye significantly 
reduced IOP, but had no effect in the contralateral eye. 
Data presented as mean ± SEM. 
* Significantly reduced when compared to baseline (t=0),p <0.001, n=10. 
92 
Effect on contralateral eye 
IOP changes in the contralateral control eye (OS) were recorded after treatment 
with WIN 55212-2, 0-1812, 0-2545 or vehicle. There was no apparent cross over effect 
in the contralateral control eye even at the highest concentration of WIN55212-2 1.0% 
(Figure 18). For example, IOP was reduced from 16.2 ±0.9 mmHg at baseline (t=0) to 
9.0 ±0.5 mm Hg after 60 min in the treated eye. There was no concomitant change in the 
untreated eye (p - 0.59); i.e. IOP was 10.1 ± 0.5 mmHg at baseline and 10.4 + 0.4 mmHg 
after 60 min (n=10). Also, after treatment with 0-1812 or 0-2545, IOP in the 
contralateral eye was unaffected (see Figure 15 and 16). Sedation, itself, did not 
significantly alter IOP in the hypertensive eye. 
Effect of CB1 receptor antagonism on Q-1812 or Q-2545 
Topical application of 0-1812 1.0% alone reduced IOP by 26 % after 30 min and 
38 % by 120 min (Figure 1). After pretreatment with CB1 antagonist, SR141716 (2mM), 
topical treatment with 0-1812 had no effect on IOP at 30, 60 and 120 min, indicating 
significant antagonism of 0-1812 by SR141716 (Figure 19). 
When administered alone, 0-2545 1.0% reduced IOP by 18 % after 30 min and 
23 % by 120 min (Figure 2). Pretreatment with CB1 antagonist, SR141716 (2mM), did 
not reduce IOP within 30 min. However, a slight reduction of 9 ± 0.4% in IOP was 
observed 60 min after instillation of 0-2545, which recovered to baseline value after 120 
min. Topical administration of SR141716 (2mM to 0.02mM) alone had no effect on IOP 
(data not shown). No crossover effects were seen in the contralateral eye. 
93 
- • - 1.0% 0-1812 
- O - 1.0% 0-2545 















-30 30 60 
Time (min) 
90 120 150 
Figure 19: Effect on IOP of CB1 antagonist, SR141716, followed by 0-1812 or 0-2545. 
CB1 antagonist (2mM), SR141716, was applied topically 30 min (see arrow) prior to 
administration of each cannabinoid (t = 0 min). Data presented as mean ± SEM. N=6. 
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Figure 20: Effect on IOP of CB1 antagonist, SR141716, followed by WIN55212-2. 
CB1 antagonist, SR141716, was applied topically 30 min (see arrow) prior to 
administration of WIN55212-2 (t = 0 min). Data presented as mean ± SEM. 
* Significantly reduced from baseline (t=0),p<0.05. 
t Significantly greater than 1.0% WIN55212-2 alone treatment, p<0.05. 
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Effect of CB1 receptor antagonism on WIN 55212-2 
Topical application of WIN55212-2 1.0% alone reduced IOP by 32 % after 30 
min and 52% by 120 min (Figure 17). After pretreatment with CB1 antagonist, 
SR141716 (2mM), the maximal reduction of only 8.0±2.1% occurred at 30 min (n=3). 
This reduction was significantly less than WIN55212-2 alone (p=0.009), but significantly 
lower than baseline (p=0.03, n=3, Figure 20). IOP recovered to baseline within 120 min 
indicating significant antagonism of WIN55212-2 (p<0.001, compared to WIN55212-2 
alone, n=3). 
The effect of SR141716 on the response to WIN55212-2 was concentration 
dependent. After decreasing the concentration of SR141716 50 fold (0.04 mM), 
WIN55212-2 decreased IOP by 20% at 30 min and by 10% at 120 min (p=0.15, and 
p<0.001 respectively when compared to WIN55212-2 alone;p=0.02 andp=0.05 
respectively when compared to baseline, n=3). After a 100 fold decrease (0.02 mM), 
WIN55212-2 maximally reduced IOP by 23% at 30 min and by 14% at 120 min (p=0.29, 
andp=0.04 respectively when compared to WIN55212-2 a\one;p=0.02 andp=0.06 
respectively when compared to baseline, n=3). 
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Figure 21: Effect of CB2 antagonist, SR 144528, followed by 0-1812 or 0-2545 on IOP 
was tested for 120 min. 
CB2 antagonist was applied topically 30 min prior to administration of each cannabinoid. 
Data presented as mean ± SEM. 
* Significantly reduced from baseline (t=0),p<0.05. 
Effect of CB2 receptor antagonism on 0-1812 or 0-2545 
Effects of pretreatment with CB2 antagonist, SR144528 (2mM), on IOP were 
studied after topical administration of 0-1812 1.0%, or 0-2545 1.0% (Figure 21, n=3). 
After pretreatment with SR144528, 0-1812 1.0% reduced IOP by 11 ± 0.6% at 30 min 
(p<0.0001 when compared to 0-1812 alone;p=0.05 when compared to baseline, n=3) 
and by 13 ± 1.3% mmHg after 120 min (p=0.009 when compared to 0-1812 alone; 
p=0.05 when compared to baseline, n=3). 
In the presence of SR144528, the IOP response to 0-2545 1.0 % was decreased 
by 26 ± 0.4 % after 30 min (p=0.15 when compared to 0-2545 alone; p=0.03 when 
compared to baseline, n=3) and by 28 ± 0.9% after 120 min (p=0.005 when compared to 
0-2545 alone; p<0.0001 when compared to baseline, n=3). Topical administration of 











Figure 22: Inhibition of WIN55212-2 by the CB2 antagonist, SR 144528. 
CB2 antagonist was applied topically 30 min prior to administration of WIN55212-2. 
Data presented as mean ± SEM. 
* Significantly different from baseline (t=0),p<0.05. 
f Significantly different from WIN55212-2 1.0% alone treatment, p<0.05. 
Effect of CB2 receptor antagonism on WIN 55212-2 
Pretreatment with CB2 antagonist, SR144528 (0.02mM) did not significantly 
inhibit the effects of WIN55212-2 1.0% (Figure 22, n=3). Following SR144528 
pretreatment, IOP was reduced from a baseline of 19.5±0.4 mmHg to 9.0±0.4 mmHg at 
30 min (p= 0.13 when compared to WIN55212-2 alone;p= 0.05 when compared to 
baseline, n=3) and 9.0±0.1 mmHg at 120 min (p=0.18 when compared to WIN55212-2 
alone; p-0.03 when compared to baseline, n=3). 
When pretreated with higher doses of SR144528 (0.04mM or 2mM), the 
hypotensive effects of WIN55212-2 1.0% diminished. After doubling the concentration 
(0.04 mM), WIN55212-2 decreased IOP by 30% at 30 min and by 25% at 120 min 
(p=0.80, andp= 0.01 respectively when compared to WIN55212-2 alone;p=0.02 and 
p=0.05 respectively when compared to baseline, n=3). A further SR144528 increase (to 
2mM), blocked the WIN55212-2 mediated IOP effect (for 30 and 120 min,p=0.003 and 
p=0.001 respectively when compared to WIN55212-2 alone;/?=0.11 andp=0.17 
respectively when compared to baseline, n=3). 
Effects of WIN55212-2 on heart rate and blood pressure 
Even at the highest concentration tested 0-1812, 0-2545 or WIN55212-2 (1.0%) 
had no effect on heart rate or blood pressure. Although, after administration of WIN 
55212-2, heart rate apparently changed from 434 ±12 bpm at baseline to 414 ±10 bpm at 
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120 min, this change was not significant (p=0.70). Likewise, neither systolic nor 
diastolic blood pressure changed significantly (p=1.00,p=0.67, respectively compared to 
baseline). 
Examination for ocular irritation 
Slit lamp examination conducted at the end of each experiment revealed no signs 
of ocular toxicity attributable to vehicle, 0-1812, 0-2545, WIN55212-2, SR141716, or 
SR144528. No signs of inflammation, conjunctival chemosis/swelling, conjunctival 
discharge, aqueous fibrin/flare, loss of the pupillary light reflex, obscuration of iris 
structures, or corneal opacity were observed. In all treatment groups mild central corneal 
staining was noted consistently. However, similar corneal staining also occurred in the 
untreated control eyes. This finding was most likely a result of repeated applanation with 
the Goldmann tonometer rather than a drug- or vehicle-induced effect. 
Corneal thickness 
Confocal examinations of the cornea were performed at conclusion of each 
experiment. Treatment with 0-1812, 0-2545 or WIN 55212-2 did not change central 
corneal thickness as it remained at a baseline thickness of 320±25 um. 
Discussion 
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It has been over a decade since a new class of pharmacologic agents was 
introduced for the clinical management of glaucoma25. Currently available therapeutic 
approaches for the treatment of glaucoma include prostaglandin analogs, beta-adrenergic 
blockers, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors and cholinergic 
agonists. Each of these has a well known profile of clinical response and adverse effects. 
Up to 50% of patients cannot be maintained on single drug therapy; most require use of 
two or even three drugs to control their IOP . Even the first line agent for the treatment 
of glaucoma, timolol, as monotherapy controlled IOP in only 98 of 155 patients (63.2%) 
34. More recently, in the Ocular Hypertension Treatment Study, 40% of patients 
randomized to treatment required more than one medication to achieve the 20% reduction 
goal35. 
For over thirty years cannabinoids have been touted for their potential to decrease 
IOP 6. However, cardiovascular and psychotropic effects complicate systemic 
administration ' . Numerous studies showed that systemic administration of 
cannabinoids produced an unwanted reduction in systolic and diastolic blood pressure, 
decreased heart rate and variable changes in pupil diameter 42~44. Moreover, the 
associated psychotropic effects of these agents are well documented 45. 
Topical administration of cannabinoids offers the theoretical advantage of 
providing desirable local ocular effects with minimal, if any, systemic side-effects. 
However, poor cannabinoid solubility has hindered preparation of a suitable topical 
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dosage form, resulting in an inadequate effect on IOP 142'147. Vehicles with potential for 
dissolving lipophilic cannabinoids include sesame oilI48 '149, mineral oil148' 15°, 
polyethylene glycol 141'142, Tween 80 I48, and submicron aqueous emulsions 151. While 
these agents have the ability to dissolve the lipophilic cannabinoids, they may also permit 
sufficient systemic absorption associated with undesirable systemic effects. For example, 
topical application of A 9 THC in a submicron emulsion significantly reduced IOP in 
rabbits, but systemic effects were also noted 151. 
Tocrisolve™, a proprietary preparation, is a vehicle designed for lipophilic 
compounds, such as cannabinoids and vanilloids. Tocrisolve is composed of 1:4 soya oil 
and water and is emulsified with the block copolymer Pluronic F68. In the past we have 
used 2-hydroxypropyl-P-cyclodextrin as a vehicle to dissolve cannabinoids. Both 2-
hydroxypropyl-P-cyclodextrin and Tocrisolve™ are good solvents for WIN55212-2. 
However, Tocrisolve™ not only dissolves up to 2% in WIN55212-2 compared to 1% in 
2-hydroxypropyl-P-cyclodextrin but also does not require ethanol to promote solubility 
90. In this study, acute application of WIN55212-2, dissolved in Tocrisolve™ and 
applied topically, produced a significant reduction in IOP. Moreover, there was a notable 
lack of systemic effects, e.g. heart rate and blood pressure. In a recent study, 4 weeks of 
daily topical treatment of rats with WIN55212-2 in Tocrisolve™ did not cause local 
ocular toxicity, i.e. ocular inflammation, conjunctival chemosis/swelling, conjunctival 
discharge, aqueous flare or fibrin, diminished corneal light reflex, iris or corneal opacity, 
or corneal vascularization/staining 90. This excellent tolerability profile supports the 
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potential use of these cannabinoid emulsions in the management of glaucoma in humans 
where long term treatment is needed. 
In normotensive rabbits Song and Slowey speculated that WIN55212-2 exerts its 
ocular hypotensive effect in part through activation of CB1 receptors in the eye 16. 
Studies designed to identify the distribution of cannabinoid receptor mRNA and protein 
in ocular tissues support this hypothesis. Using reverse transcriptase polymerase chain 
reaction technology, CB1 mRNA transcripts were expressed at significant amounts in the 
retina, ciliary body and iris, but CB2 mRNA transcripts were undetectable in human eyes 
51. Likewise, a similar distribution of CB1 mRNA, with an absence of CB2 mRNA, was 
found in eyes from ocular normotensive rats 13. However, there is recent evidence for 
CB2 receptors on trabecular meshwork cells. Stimulation of these receptors with the CB2 
agonist, JWH015, increased the aqueous humor outflow, thus contributing to their ocular 
hypotensive effect53. 
While the mechanism is unknown, pharmacological and histological studies 
support a direct role for CB receptors in ocular tissues of the human eye, including the 
ciliary epithelium, trabecular meshwork, Schlemm's canal, ciliary muscle, ciliary body 
vessels and retina 152. Also, Sugrue suggests that cannabinoid receptors in the retina may 
convey neuroprotection to retinal ganglion cells 22. In this study, topical application of 
0-1812 or 0-2545 was compared to WIN55212-2 using ocular hypertensive rats. The 
effects of WIN55212-2 1.0% and 0-1812 1.0% were comparable, while 0-2545 1.0% 
was not as effective. Evidence from this study also indicates that the effect of 0-1812, 
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0-2545 and WIN55212-2 is mediated primarily by CB1 receptor activation, congruent 
with the ability of the CB1 antagonist, SR141716, to inhibit the effects of these drugs 
(1%). When pretreated with SR141716 (2mM-0.02mM), the magnitude and duration of 
drug mediated hypotensive effect was severely diminished. In this study, the effect of 
SR141716 was noted as early as 30 min lasting for the entire study period. Although IOP 
was only measured for 2hr, Boyd and Fremming have demonstrated that when given 
orally, the duration of blockade by SR141716 is upto 8 hrs 
CB1 receptors are widely distributed in the eye. The local effect of cannabinoids 
at these receptors may be multifocal and remains to be fully elucidated. At the level of 
the ciliary body CB1 receptor-mediated control of IOP is likely due, at least partially, to 
decreased aqueous humor production 13'147'154'155. By contrast, CB1 receptors present in 
the trabecular meshwork may increase trabecular outflow 14'52'156. Either site could be 
easily reached in therapeutic concentrations following topical application of CB1 
agonists, as was done in the current study. Others have speculated that IOP effects could 
also be non-receptor mediated 16. 
The role of CB2 receptors in IOP control has not been definitively determined. 
The Ki values of the CB2 antagonist (SR144528, Ki [CB2] = 0.6 nM, and Ki [CB1] = 
437 nM) used in this study were determined in Chinese hamster ovary cells whose 
membranes express CB2 receptors 146. The topical dose of SRI44528 used in the current 
study was considerably higher (2.0mM-0.02mM) than the Ki [CB2] of 0.6 nM. Although 
the data indicate a preferential contribution of CB1 to CB2 receptors in the 0-1812, O-
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2545 and WIN 55212-2 mediated IOP reduction, the differences in receptor selectivity of 
SR144528 and SR141716 in vivo are much less than expected from the in vitro 
experiments. This may be related to a number of factors including the amount of 
antagonist delivered to the receptors or the residency of the antagonist on the receptor. 
When administered topically in rabbits, the maximum concentration of timolol in 
the vitreous humor was a hundred-thousandth of that in the drop 157, indicative of the type 
of reduction in concentration that might be expected in our model. With a difference in 
vivo Ki, the blockade of 0-1812 and WIN55212-2 observed at the higher concentrations 
of SR144528 could be due to administration of this agent in concentrations greatly 
exceeding its Ki [CB2] and approaching its Ki [CB1]. Thus, nonspecific binding to the 
CB1 receptor may have blunted the effect of 0-1812 and WIN55212-2 in this setting. 
Although CB1 receptor effects are predominant, WIN55212-2 may also exhibit mixed 
agonist activity in some tissues suggesting that there may be some role for CB2 receptors 
in cannabinoid-mediated IOP control. 
In this study we showed that topically applied novel cannabinoids, 0-1812 and O-
2545, effectively decrease IOP in a rat model of ocular hypertension. This effect on IOP 
was dose dependent and mediated predominantly through CB1 receptors. Equally 
important was a notable lack of systemic effects or local toxicity to ocular structures. 
Thus, a new class of medications, topically administered cannabinoids, to the current 
armamentarium offers the clinician more alternatives in the management of glaucoma. 
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CHAPTER VIII 
O-COMPOUNDS CONFER NEUROPROTECTION VIA A CB1 
MEDIATED PATHWAY 
Introduction 
The visual pathway begins at the photoreceptors. After light stimulation, a 
photoisomerization reaction in the rods and cones, initiates the visual cycle generating an 
electrical signal which traverses the visual pathway terminating in the visual cortex. 
While the electrical activity is transmitted to the visual cortex, the photoreceptors are 
replenished with trophic factors which originate from the visual cortex. Any break in the 
visual pathway leads to blindness due to either degeneration of the photoreceptors by 
termination of the trophic factors or the absence of electrical activity at the 
1 SS 
photoreceptors 
In glaucoma, risk factors such as elevated IOP, can contribute to the degeneration 
of photoreceptors especially the retinal ganglionic cells. It is postulated that NMDA 
channels are overstimulated as a result of an injury, for example hypoxia, which results in 
elevation of glutamate and subsequently intracellular Ca [2+] leading to excitotoxicity 6' 
49'. NMDA receptors are expressed in both outer and inner retina, mostly RGC but 
limited in rods and bipolar cells 159'160. However, NMDA channels and glutamate are 
necessary for signal transduction especially in the bipolar cells 24'161. 
Naturally occurring delta-9-THC and synthetic cannabmoids, such as WIN 
55212-2, protect neural cells from excitotoxicity as demonstrated in brain tissue and also 
against perinatal brain lesions 162"164. Increase in reactive oxygen species as a result of 
excessive NMD A signalling can also be countered by delta-9-THC 165. More recent 
finding suggests that NMDA mediated Ca [2+] entry into cells triggers cannabinoid 
signalling I66. 
In the previous chapter the efficacy of newly synthesized O-compounds was 
established. Considering that the O-compounds are derivatives of delta-9-THC, they 
should also be neuroprotective. This is a pilot study to evaluate the neuroprotective 
effects of 0-1812 and 0-2545 in a rat NMDA model. We also tested the receptor 
specific neuroprotective effects by blocking the CB1 receptors with SR141716 and 
blocking CB2 receptors with SR144258. Additionally, the specific effect of 
cannabinoids on Ca (2+) influx was examined. 
Experimental Design 
To induce retinal damage, male Sprague Dawley rats weighing -250 gm, 50 to 
55 days old (Harlan, Indianapolis, IN) underwent intravitreal NMDA injections. To 
determine the neuroprotective effects of the cannabinoids, ERG responses were 
compared between NMDA only treatment and NMDA + (0-1812 or 0-2545) treatment. 
After baseline ERG measurements, animals were injected with NMDA. ERG was 
measured after 1 and 2 wks. For the NMD A control group, 2 îl of lOmM NMD A was 
injected into the vitreous. For cannabinoid treated groups, 20 jo.1 of either 0-1812 1.0% 
or 0-2545 1.0% was administered topically (b.i.d) for 3 days prior and for 2 days after 
the NMD A injection. To determine receptor specificity, 10 ul of either CB1 antagonist 
(SR141716, 2 mM) or CB2 antagonist (SR144258, 2 mM) was injected intravitreally 
followed 30 min later by NMD A. For these experiments, rats were also pre-treated with 
0-1812 or 0-2545 for 3 days prior and for 2 days after the NMDA and CB (1 or 2) 
receptor antagonist injection. 
ERG measurements were made scotopically using calibrated bright flashes to 
stimulate the photoreceptors. In the dark cycle, the photoreceptors are in a depolarized 
state, but when stimulated the photoreceptors repolarize and generate a characteristic 
wave pattern known as the a-wave. With NMDA toxicity, the photoreceptors along with 
the a-wave response are greatly affected 167. It is therefore sound to focus on the a-wave 
response initially to determine the extent of neuroprotection in the photoreceptors. The 
contralateral normal eye served as an age matched negative control, e.g. response in a 
normal, untreated eye. Differences in amplitude of the a-waves between eyes treated 
with NMDA only, the positive control, and NMDA + O-compounds were calculated and 
analyzed. All data is reported as a percentage of the baseline. 
At the end of 2 wks, animals were sacrificed and eyes enucleated for histology. 
Retinas were harvested by bisecting the eyes peri-limbally and removing the anterior 
segment. The remaining posterior segment cup was flattened with 4 radial cuts after 
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which the retinal layer was carefully dissected and stained with Hematoxylin and Eosin. 
For positive identification of RGC, retinal flat mounts were compared with cross-sections 
for cell shape, placement and distribution. Cell counts were performed by knowledgeable 
masked observers. For each retina, at least 2 microscopic fields of 50 urn were captured 
per quadrant at predetermined distance from the optic cup (200 um). The total retinal 
area was approximately 500 urn . Retinal cell counts were averaged for each field and 
comparisons made between O-compound treated, contralateral control and positive 
control NMDA treated eyes. Retinal cell counts are expressed as cells per 50 urn ±SD. 
Results 
NMDA induced excitotoxicity is prevented by novel cannabinoids 
NMDA and endocannabinoids altered retinal function (Figure 23). Damage 
induced by NMDA was severe and reduced a-wave amplitude by 36±16 % (p<0.001, 
n=6) from baseline in one week. Co-administration of NMDA with 0-2545 resulted in a 
41±17 % (p<0.001, n=6) loss a-wave amplitude, similar to that of NMDA alone after one 
week. However, only 0-1812 effectively mitigated the toxic effect of NMDA in one 
week, with only a 19±13 % loss in a-wave amplitude, which while significantly less than 
baseline (p<0.01, n=6), was also a significantly smaller decrease than NMDA alone 
(p=0.05, n=6). 
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After 2 wks, NMDA induced damaged continued to progress to 46±9 % a-wave 
amplitude loss (p<0.001, n=6), but cannabinoid treatment resulted in improved retinal 
function. Lipid soluble 0-1812 was the most effective endocannabinoid as a-wave 
amplitude was only 7±12 % less than baseline after two weeks, which was not 
significantly less than baseline (p=0.08, n=6). Water soluble 0-2545 also countered the 
effects of NMDA but retinal function was significantly less than baseline (31±13 %, 
p<0.05, n=6). Thus, it was not as effective as 0-1812. 
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Figure 23: Topical treatment with 0-1812 or 0-2545 after intravitreal injection of 
NMDA. 
Retinal function was measured with electroretinography (ERG) one and two weeks after 
NMDA injection. Alterations in retinal response as a result of treatments were assessed 
by the a-wave amplitude and expressed as percent of baseline. 
* Significantly reduced from baseline, p<0.001 
| Significantly greater than NMDA alone,p<0.05 
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Table 5: Retinal function was measured with electroretinography (ERG). 
Alterations in retinal response as a result of treatments were assessed two weeks after 























* Significantly less than baseline, p<0.001 
f Significantly less than NMDA alone treatment,p<0.001 
% Significantly greater than 0-1812 alone treatment, p< 0.03 
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Neuroprotective effect in the presence of CB1 receptor antagonist 
To determine specific CB receptor involvement in neuroprotection, CB1 
antagonist SR-141716 (2mM) was injected intravitreally while either 0-1812 or 0-2545 
(2mM or 1.0%) was administered topically (Table 5). After two weeks, the CB1 
antagonist attenuated the effects of 0-1812 as the a-wave amplitude loss was 45±17 % 
which was significantly less than baseline and 0-1812 alone (p<0.001, n=6). SR-141716 
did not have an effect on 0-2545 action as a-wave amplitude loss was 32±8%, similar to 
that of 0-2545 alone treatment (31±13%). 
Neuroprotective effect in the presence of CB2 receptor antagonist 
CB2 receptor antagonist, SR-144258 (2mM), was injected intravitreally to 
determine the role of CB2 receptors in neuroprotection (Table 5). Either 0-1812 or O-
2545 (2mM or 1.0%) was administered topically. After two weeks, SR-144258 did not 
have any effect on the activity of 0-1812 as a-wave loss was 7±10 % which was similar 
to 0-1812 alone treatment (7±12 %). SR-144258 also did not effect on 0-2545 action as 
a-wave amplitude loss was 32±8%, similar to that of 0-2545 alone treatment (31±13%). 
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Figure 24: Flat mounted retinas stained with H&E. 
Retinas were harvested at terminal point of the experiment (two weeks). 
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Endocannabinoids preserve retinal cell density 
Representative retinas from each group were analyzed for morphological changes 
(Figure 24). The analysis of RGC count was limited to the retinal flat mounts because 
the difficulty in obtaining consistent and comparable results with cross-sections. Also, 
the retinal damage was not localized to a particular area; therefore, using cross sections to 
assess morphological changes in the retina would have been less representative than the 
retinal flat mounts. Retinal ganglionic cells were positively identified in the flat mounts 
by comparing attributes (e.g. cell shape, distribution) with cross sections. After NMDA 
injection RGC cell density was significantly reduced to 46.2±22.3 compared to 101±5.6 
in the contralateral control (p<0.001). After treatment with 0-1812 or 0-2545 RGC cell 
density was 76.4±12.1 and 67.4±6.5 respectively. Cell density was significantly greater 
in the cannabinoid treated groups compared with NMDA alone (p=0.001). Also, both 
cannabinoids were equally efficacious as both had a similar effect to prevent retinal cell 
loss (p=0.58). 
O-compounds inhibit Ca [2+] influx 
In this pilot experiment the role of Ca [2+] influx as the mechanism of action for 
neuroprotection was investigated. Experiments were performed on transformed rat retinal 
ganglionic cells (RGC-5) with NMDA as a positive control. After NMDA (ImM) 
treatment, cells were incubated with 10 uM of either 0-1812 or 0-2545 (Table 6). After 
NMDA only treatment, the calcium signal after 60 min was 445% higher than baseline. 
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With 0-1812 treatment, Ca [2+] influx was much less than that of NMD A alone after 60 
min as the calcium signal was increased by 14%. After 0-2545 treatment, the calcium 
signal was increased by 303% compared to baseline. 
Discussion 
Neuroprotection is an important strategy to combat the irreversible loss of retinal 
ganglionic cells and eventually the optic nerve. While risk factors such as elevated IOP, 
ischemia and genetics play an important role in the progression of retinal neuropathy, 
they all share a common characteristic i.e. loss of loss of retinal cells especially the 
ganglionic cells 26. While the specific trigger is unknown, experimental evidence 
suggests that retinal cells undergo apoptosis26'140,168"170. Therapies that address both 
neuroprotection and reduce risk factors offer the greatest potential to combat retinal 
degenerative disorders. 
In glaucoma, the most likely mechanism for retinal cell apoptosis is by 
overstimulation of sodium channels, namely NMD A, that increase basal glutamate levels 
leading to excitotoxicity23'26. In addition to NMDA channels, metabotropic receptors, 
such as mGlu, can also elevate glutamate levels 17M73. Excess glutamate via the NMDA 
receptor increases intracellular Ca [2+] and targets the cell for apoptosis 23'26. NMDA 
receptors, therefore, represent a therapeutic target for neuroprotection. In fact, NMDA 
antagonists, such as MK801 and memantine, have shown to be neuroprotective in rat 
ocular hypertensive models 119 '171 'm. Memantine failed to show neuroprotection in 
clinical trials. 
Table 6: Percent increase in Ca [2+] influx in RGC-5 cells as a result of NMD A, 


































It is desirable that new glaucoma drugs target the reduction of the risk factors, 
such as elevated IOP, as well as preserve retinal cells from apoptosis. In chapter 7, the 
IOP reduction potential of the synthetic O-compounds was demonstrated. The lipophilic 
0-1812 reduced IOP to a greater extent than the hydrophilic 0-2545. Reduction of 
intraocular pressure, while being a sound strategy for glaucoma treatment, does not treat 
the underlying cause of glaucoma, retinal degeneration. Currently available drugs for 
glaucoma only reduce IOP. Data from this study suggest that O-compounds are 
neuroprotective, i.e. they retain the density and functionality of the photoreceptor and 
ganglionic cells. In electroretinographic evaluation two weeks after NMDA treatment, 
severe ERG a-wave deficits were observed. Concomitant treatment with either 0-1812 
or 0-2545 reduced the a-wave amplitude loss, thereby preserving photoreceptor function. 
This effect was significantly better after 0-1812 treatment than 0-2545. These findings 
also corroborated with histology obtained from retinal flat mounts. Retinas from a 
subsection of animals were removed and flat mounted and ganglionic cell density 
determined two weeks after the induction of retinal damage by NMDA or after treatment 
with NMDA + either 0-1812 or 0-2545. Both O-compounds mitigated the NMDA 
induced ganglionic cell loss; however, 0-1812 was more efficacious. 
In normotensive rabbits Song and Slowey speculated that cannabinoids such as 
WIN 55212-2 exerted ocular effects in part through activation of CB1 receptors in the 
eye 16. Studies designed to identify the distribution of cannabinoid receptor mRNA and 
protein in ocular tissues support this hypothesis. Using reverse transcriptase polymerase 
chain reaction technology, CB1 mRNA transcripts were expressed at significant amounts 
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in the retina, ciliary body and iris but CB2 mRNA transcripts were undetectable in human 
eyes 51. Likewise, a similar distribution of CB1 mRNA, with an absence of CB2 mRNA, 
was found in eyes from ocular normotensive rats 13. CB1 receptors are widely distributed 
in the eye. The local effect of cannabinoids at these receptors may be multifocal and 
remains to be fully elucidated. While at the level of the ciliary body CB1 receptor-
mediated control of IOP is likely due, at least partially, to decreased aqueous production, 
their effect on neuroprotection is not fully understood 13'147'154'155. In our experiments, 
the CB antagonists affected IOP reduction as well as neuroprotection. The CB1 
antagonist blocked the neuroprotective action of 0-1812, a potent CB1 receptor agonist, 
but had no effect on the action of 0-2545, a mixed CB receptor agonist. The CB2 
receptor antagonist did not have an effect on the actions of either O-compound. These 
results suggest that the neuroprotective effect could easily be mediated by the CB 1 
receptor, which is similar to the proposed mechanism of IOP reduction. Kim et. al., have 
also reported CB1 activation as a possible mechanism of neuroprotection against NMD A 
toxicity 175. 
Although both O-compounds exhibit similar affinities for the CB1 receptor, for 
0-1812 (CB1 Ki= 3.4±0.5 nM, CB2 Kt = 3870±235 nM)
79 and for 0-2545 (CB1 Kt = 
1.5±0.2 nM, CB2 Kt = 0.32±0.02)
87, the differences in effect can be attributed to 
variabilities in ocular penetration. Receptor activation is a function of drug availability at 
the target site. It well known that lipid soluble compounds have a constant and higher 
bioavailability in the ocular environment than water soluble compounds 176. In chapter 6, 
the ocular penetration of 0-1812 was shown to be greater than 0-2545. This variability 
in ocular penetration affects both neuroprotection and IOP reduction potential. After a 
single dose of 0-1812, a 2 nM concentration was maintained in the vitreous chamber for 
120 minutes, while 0-2545 remained for only 80 minutes. Pretreatment with 0-1812 for 
3 days prior and two days after NMD A injection, a concentration of at least 2 nM would 
have been maintained in the vitreous chamber to mitigate the effects of NMD A. It is, 
therefore, likely that a pharmacologic concentration might not have been achieved with 
the hydrophilic drug to induce significant neuroprotection. 
After NMD A injection, toxic effects can be observed in the retina in as little as 3 
hours with a peak effect at 12 hours 177. In order for a drug to have an effect, a 
pharmacological concentration must be achieved at the retina during the initial stages of 
NMDA toxicity, i.e. within 3 hours. With topical (b.i.d) pretreatment for 3 days and an 
additional 2 days after the NMDA injection, O-compounds were present in sufficient 
concentration at the retina to mitigate the toxic effects of NMDA. When ERG 
measurements were obtained after 1 week, the NMDA treated group showed a significant 
loss in ERG function which continued to decline. In the presence of both O-compounds, 
although there was some loss of function at 1 week, it improved over the period of 2 
weeks. This phenomenon could be due to the toxic shock suffered by the retinal cells 
which could disrupt, fragment or ablate retinal cells 178. Retinal function could also be 
compromised due to the disruption of the osmotic balance after intravitreal injections 179. 
It is important to note that even with a limited dosing regimen, substantial 
neuroprotective effects were observed with either O-compound; however, 0-1812 was 
significantly more effective. 
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In an initial attempt to determine the mechanism of action, the role of intracellular 
Ca [2+] influx was considered. In this pilot experiment, using isolated retinal ganglionic 
cells, both O-compounds reduced the influx of Ca [2+]. This needs to be explored further 
to identify downstream signalling events leading to apoptosis. In conclusion, O-
compounds are a new class of drugs that are efficacious ocular hypotensive and 
neuroprotective agents. They can reduce the associated risk factors such as elevated IOP 




EFFECT OF COMBINING CANNABINOIDS WITH COMMONLY 
PRESCRIBED GLAUCOMA MEDICATIONS ON INTRAOCULAR 
PRESSURE IN A RAT OCULAR HYPERTENSIVE MODEL 
Introduction 
Despite the currently available therapeutic approaches for the treatment of 
glaucoma, up to 50% of patients cannot be maintained on single drug therapy; most 
require use of two or even three drugs to control their IOP 9T. Even the first line agent for 
the treatment of glaucoma, timolol, as monotherapy controlled IOP in only 98 of 155 
patients (63.2%)34. More recently, in the Ocular Hypertension Treatment Study, 40% of 
patients randomized to treatment required more than one medication to achieve the 20% 
reduction goal . 
Commonly used classes of agents include (3-adrenergic antagonists e.g. timolol, 
prostaglandin analogs e.g. latanoprost and a-adrenergic agonists e.g. brimonidine 98. 
Timolol lowers IOP by decreasing aqueous humor production while brimonidine, in 
addition to decreasing aqueous humor production, has the added benefit of increasing 
uveoscleral outflow " . These two drugs when used concomitantly have an additive effect 
on IOP " . Other popular agents are carbonic anhydrase inhibitors e.g. dorzolamide 
and prostaglandin analogs e.g. latanoprost. Dorzolamide reduces aqueous humor 
formation while latanoprost increases uveoscleral outflow ' . Endocannabinoid 
analogs are a new class of agents that are efficacious ocular anti-hypertensives. These 
analogs exert their effects by activating the cannabinoid receptor system (CB1/CB2). 
Their exact mechanism of action is largely unknown. The purpose of this study is to 
compare efficacy of timolol, dorzolamide, travoprost or brimonidine as monotherapy or 
in combination with endocannabinoid analogs, 0-1812 or 0-2545, in a rat glaucoma 
model. 
Experimental design 
Sprague Dawley rats were randomly assigned to receive 20 ul of either timolol 
0.5%, 0-1812 1.0%, 0-2545 1.0%, brimonidine 0.2%, dorzolamide 2%, travoprost 
0.004% alone or in combination, applied topically to the right eye. For combination 
therapy, timolol 0.5%, dorzolamide 2.0% or brimonidine 0.1% were applied topically 
followed 10 minutes later with either 0-1812 1.0% or 0-2545 1.0%. The contralateral 
eye (OS) served as the untreated control. At the beginning of each experiment, animals 
were sedated (ketamine 40 mg/kg and acepromazine 6 mg/kg) and baseline IOP, heart 
rate (HR), blood pressure (BP) measurements (t=0) were obtained. IOP measurements 
were obtained 30, 60 and 120 min after drug administration. HR and BP were also 
measured at baseline and towards the end of the experiment. Before and at the 
conclusion of each experiment, all eyes were examined and graded by slit lamp for signs 
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Figure 25: 0-1812 1.0% and timolol 0.5% were applied alone or in combination and 
IOP recorded for 120 min. 
Data are normalized to baseline measurements and presented as mean ± SEM. 
* Significantly reduced compared to baseline (time = 0 min) (p<0.05), 
f Significantly reduced compared to timolol and combination (p<0.05) 
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Results 
Combination of 0-1812 and timolol 
Timolol and 0-1812 were administered alone or in combination to evaluate their 
effect on IOP (Figure 25). At the beginning of the experiment, baseline IOP 
measurements were obtained after which 0-1812 1.0% or timolol 0.5% was applied (time 
= 0 min, baseline, n=4 per group). For combination treatment, timolol 0.5% was applied 
first followed 10 minutes later with 0-1812 1.0% at baseline (t=0). 
After 30 min, a single dose of timolol reduced IOP from 23±0.6 mmHg at 
baseline to 16±0.8 mmHg, 0-1812 reduced IOP from a baseline of 27+1.2 mmHg to 
17+0.9 mmHg while the combination resulted in an IOP of 19+0.6 mmHg from a 
baseline of 27±1.0 mmHg (n=4). After this time point, no further reduction in IOP was 
observed. After 60 min, IOP remained significantly reduced in all treatment groups when 
compared to the baseline. However, IOP reduction achieved with 0-1812 was 
significantly greater than that of timolol alone or the combination. 
The experiment was terminated 120 min after drug administration. A final IOP 
measurement of 20+0.4 mmHg was obtained in the timolol 0.5% treatment group, 18+0.4 
mmHg for O-1812 1.0% and 21 ±0.5 mmHg for the combination. All treatments 
significantly reduced IOP compared to baseline (p<0.05, n=4 per group). 0-1812 was 
most efficacious compared with timolol or the fixed dose combination, no additive or 
synergistic effects were observed after combination therapy. 
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Figure 26: 0-1812 1.0% and dorzolamide 2% were applied alone or in combination and 
IOP recorded for 120 min. 
Data are normalized to baseline measurements and presented as mean ± SEM. 
* Significantly reduced compared to baseline (time = 0 min) (p<0.05) 
f Significantly reduced than the combination (p<0.05) 
127 
Combination of 0-1812 and dorzolamide 
The effects of dorzolamide and 0-1812 on IOP were evaluated when applied 
alone or in combination (Figure 26). At the beginning of the experiment, baseline IOP 
measurements were obtained after which 0-1812 1.0% or dorzolamide 2.0% was applied 
(n=4 per group). For the combination treatment, dorzolamide 2.0% was applied first 
followed 10 minutes later by 0-1812 1.0% at baseline (1=0). 
After 30 min, dorzolamide alone reduced IOP from a baseline of 23±0.3 mmHg to 
14±0.5 mmHg, 0-1812 reduced IOP from a baseline of 27+1.2 mmHg to 17+0.9 mmHg 
while the combination treatment reduced IOP from a baseline of 24+1.1 mmHg to 19+1.2 
mmHg (n=4). At this time point, combination of 0-1812 and dorzolamide did not 
produce an additive or synergistic reduction in IOP. 
After 60 min, dorzolamide had the greatest effect with an IOP of 13+1.2 mmHg 
compared to 17+0.4 mmHg for 0-1812 and 17+0.5 mmHg for the combination. 
Although significantly reduced from baseline, the effect of dorzolamide was not 
sustained past 60 min. After 120 min, the IOP reduction achieved with 0-1812 alone and 
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Figure 27: 0-1812 1.0% and brimonidine 0.2% were applied alone or in combination 
and IOP recorded for 120 min. 
Data are normalized to baseline measurements and presented as mean ± SEM. 
* Significantly reduced compared to baseline (time = 0 min) (p<0.05) 
f Significantly reduced than brimonidine alone (p<0.05) 
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Combination of 0-1812 and brimonidine 
Brimonidine and 0-1812 were administered alone or in a fixed dose combination 
to evaluate their effect on IOP (Figure 27). At the beginning of the experiment, baseline 
IOP measurements were obtained after which 0-1812 1.0% or brimonidine 0.2% were 
applied (n=4 per group). For combination treatment, brimonidine 0.2% was applied first 
followed 10 minutes later with 0-1812 1.0% at baseline (1=0). 
After 30 min, a single dose of brimonidine reduced IOP from a baseline of 23±1.5 
mmHg to 16±1.1 mmHg, 0-1812 reduced IOP from a baseline of 27±1.2 mmHg to 
17+0.9 mmHg while the combination treatment reduced IOP from a baseline of 25±0.8 
mmHg to 14±0.7 mmHg (n=4). At this time point, the fixed dose combination 
significantly reduced IOP compared to brimonidine alone but was not different than O-
1812 alone. 
In all treatment groups, maximal effect was achieved 30 min after drug 
administration after which IOP reverted towards baseline. At the end of the experiment 
(120 min), IOP in the 0-1812 group (18±0.4 mmHg) and in the combination group 
(21±1.2 mmHg) was still less than baseline. However, the brimonidine treatment group 
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Figure 28: 0-2545 1.0% and timolol 0.5% were applied alone or in combination and 
IOP recorded for 120 min. 
Data are normalized to baseline measurements and presented as mean ± SEM. 
* Significantly reduced compared to baseline (time = 0 min) (p<0.05) 
f Significantly reduced than combination (p<0.05) 
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Combination of 0-2545 and timolol 
The efficacy of timolol and 0-2545 when administered alone or in a fixed dose 
combination was evaluated (Figure 28). At the beginning of the experiment, baseline 
IOP measurements were obtained after which 0-2545 1.0% or timolol 0.5% were applied 
(n=4 per group). For the combination treatment timolol 0.5% was applied first followed 
10 minutes later with 0-2545 1.0% at baseline (time = 0 min, n=4 per group). 
After 30 min, a single dose of timolol reduced IOP from 23±0.6 mmHg at 
baseline to 16±0.8 mmHg, 0-2545 reduced IOP from 25+1.4 mmHg to 18±0.4 mmHg 
while the combination resulted in a decline in IOP from 28±0.3 mmHg to 23±1.0 mmHg 
(n=4). At this time point, the combination of 0-2545 and timolol was least efficacious 
compared with 0-2545 or timolol alone. 
Maximal efficacy for timolol and the combination was achieved after 30 min, and 
after 60 min with 0-2545. At the end of the experiment (120 min) IOP remained 
decreased in the 0-2545 group (18±0.5 mmHg) but tended to return toward baseline in 
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Figure 29: 0-2545 1.0% and dorzolamide 2% were applied alone or in combination and 
IOP recorded for 120 min. 
Data are normalized to baseline measurements and presented as mean ± SEM. 
* Significantly reduced compared to baseline (time = 0 min) (p<0.05) 
f Significantly reduced than combination (p<0.05) 
133 
Combination of 0-2545 with dorzolamide 
The effects of dorzolamide and 0-2545 on IOP were evaluated when applied 
alone or in combination (Figure 29). At the beginning of the experiment, baseline IOP 
measurements were obtained after which 0-2545 1.0% or dorzolamide 2.0% were 
applied (n=4 per group). For the combination treatment, dorzolamide 2.0% was applied 
first followed 10 minutes later with 0-2545 1.0% (n=4). 
After 30 min, a single dose of dorzolamide reduced IOP to 14±0.5 mmHg from a 
baseline of 23±0.3 mmHg, 0-2545 reduced IOP to 18±0.4 mmHg from a baseline of 
25+1.4 mmHg while the combination treatment reduced IOP to 20±0.6 mmHg from a 
baseline of 28±0.6 mmHg (n=4). At this time point, dorzolamide was more efficacious 
than either 0-2545 alone or the combination (p<0.05, n=4). 
Dorzolamide treatment reduced IOP to 13±1.2 mmHg after 60 min and 0-2545 
treatment reduced IOP to 18±1.0 mmHg, while their combined effect on IOP was only 
26±0.4 mmHg. The combination treatment was least efficacious as IOP was not 
significantly different than baseline after 60 and 120 min after administration. A final 
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Figure 30: 0-2545 1.0% and brimonidine 0.2% were applied alone or in combination 
and IOP recorded for 120 min. 
Data are normalized to baseline measurements and presented as mean ± SEM. 
* Significantly reduced compared to baseline (time = 0 min) (p<0.05) 
f Significantly reduced than brimonidine (p<0.05) 
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Combination of 0-2545 with brimonidine 
Brimonidine and 0-2545 were administered alone or in a fixed dose combination 
to evaluate their effect on IOP (figure 30). At the beginning of the experiment, baseline 
IOP measurements were obtained after which 0-2545 1.0% or brimonidine 0.2% were 
applied (n=4 per group). For the combination treatment, brimonidine 0.2% was applied 
first followed 10 minutes later with 0-1812 1.0% (n=4). 
After 30 min, brimonidine reduced IOP from a baseline of 23±1.5 mmHg to 
16±1.1 mmHg, 0-2545 reduced IOP from a baseline of 25+1.4 mmHg to 18±0.4 mmHg 
while the combination treatment reduced IOP from a baseline of 27±0.9 mmHg to 17±1.3 
mmHg (n=4). Although combination treatment reduced IOP beyond either drug alone, it 
was not significant. 
In all treatment groups, maximal effect was achieved 30 min after drug 
administration, after which IOP reverted towards baseline measurements except for the 
0-2545 group. At the end of the experiment (120 min), IOP reduction was sustained at 
18±0.5 mmHg in the 0-2545 group and at 22±1.3 mmHg in the combination group. 
However, the brimonidine treatment reverted to 22±0.5 mmHg which was not 
significantly different from baseline (23±1.5 mmHg). 
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Effect of travoprost on IOP 
Travoprost was administered alone and IOP monitored for 120 min. After 60 
min, IOP significantly increased from a baseline of 20.3±0.7 mmHg to 23.5±0.6 mmHg 
(p=0.009, n=4). IOP returned to 20.5±0.6 mmHg after 120 min. Because of this variable 
response in IOP, further combination study was not performed. 
Discussion 
Although increased IOP is not the sole risk factor for development and progresion 
of glaucoma, therapies aimed at reducing IOP are beneficial for clinical management of 
glaucoma 35,184. It has been reported that even after a 1 mmHg reduction in IOP, the risk 
for glaucoma progression decreases by 10%2. With currently available drugs, almost 
75% of patients required combination therapy after 2 years of monotherapy to achieve 
a sufficient IOP reduction. 
In this study, topical application of 0-1812 and 0-2545 was compared with 
timolol, a B-adrenergic blocker and first line agent in glaucoma medical therapy 186"195. 
The combined effect of 0-1812 1.0% and timolol 0.5% or 0-2545 1.0% and timolol 
0.5% was significantly less from that of either drug alone suggesting that the combination 
did not produce additive or synergistic effects. Additionally, timolol made no significant 
contribution to the magnitude of the IOP reduction. It is therefore possible that the CB 
agonists may in some fashion draw on a receptor population that includes those affected 
by timolol. Vasquez et al have demonstrated that CB receptors can reduce beta 
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adrenergic receptor activity through G protein modulated effects, thus mimicking beta 
adrenergic blockade 
Dorzolamide is a carbonic anhydrase inhibitor. The exact mechanism of action of 
dorzolamide is unclear 197. Vasodilation associated with dorzolamide is independent of 
pH changes in ocular vessels and activation of nilxic oxide 198'199. Although, carbonic 
anhydrase inhibitors decrease capillary extracellular pH, the vasodilator effect might be 
potentiated by relaxation of capillary pericytes 20°. When administered alone, 
dorzolamide was as effective as 0-1812 initially in reducing IOP but the duration of 
effect was short-lived. Dorzolamide was more effective than 0-2545. When combined 
with either 0-1812 or 0-2545, no additive or synergistic effects were observed. In fact, 
the combination therapy had less on IOP than either drug alone. When combined with O-
1812, IOP was sustained for up to 120 min, an effect similar to that of 0-1812 alone. The 
sustainability of effect with the combination can be mostly attributed to 0-1812, a potent 
CB1 agonist. In comparison, the duration was shorter with dorzolamide and 0-2545. A 
suggestion for the stunted effect might be that since 0-2545 is a mixed CB agonist, it 
might not be able to activate enough CB1 receptors. Although reports on this topic are 
scarce, Maor et al has suggested that cannabinoids do not inhibit carbonic anhydrase, this 
needs further study 201. 
The a-adrenergic agonists initially reduce aqueous humor production202"204 and 
increase uveoscleral outflow after chronic application " . In this rat glaucoma model, 
brimonidine alone was the least effective agent in terms of potency and duration of effect. 
When combined with 0-1812, IOP was less than after brimonidine alone but was similar 
to that after 0-1812 alone. When combined with 0-2545, the initial reduction in IOP 
appeared to be additive, but the duration of effect was short lived. Brimonidine lowers 
IOP by both reducing aqueous humor production and increasing uveoscleral outflow and 
therefore has the theoretical advantage over other medications. However, in numerous 
studies, brimonidine alone treatment was not as efficacious and not well tolerated . 
Indeed, in our rat glaucoma model, brimonidine was the least effective agent especially 
when administered in combination with cannabinoids. In the presence of cannabinoids, 
the common G-proteins shared by both cannabinoid and a-adrenergic agonists might be 
redistributed 205. 
Prostaglandin analogs are also emerging as conventional drugs for glaucoma 
1(\f\ 0CV7 
management ' . In addition to its effect on IOP, it can also influence cyclo-
9f)8 OCiQ 
oxygenase 2 and nitric oxide synthase to confer neuroprotection ' . Administration 
of travoprost in our rat glaucoma model actually increased IOP, and, therefore, was 
deemed unsuitable for the combination experiments. In other reports, prostaglandin 
analogs have been shown to elicit a bi-phasic IOP response in rodent models, i.e. an 
initial increase followed by a decline in IOP 210. 
In this study, both 0-1812 and 0-2545 were most effacacious when administered 
alone. There were no synergistic or additive effects on IOP when combined with timolol, 
brimonidine or dorzolamide. 
CHAPTER X 
CONCLUSIONS 
It has been over a decade since a new class of pharmacologic agents was 
introduced for the clinical management of glaucoma25. The currently available drugs to 
treat glaucoma primarily reduce the risk factor of elevated intraocular pressure. These 
drugs have not shown to be neuroprotective, which would address the underlying 
pathology present in glaucoma, as well as a number of other retinal degenerative 
disorders. That being said, it is true that therapies aimed at reducing IOP are beneficial 
for clinical management of glaucoma35'184. Even a 1 mmHg reduction in IOP reduces 
the risk for glaucoma progression by 10% 2. With currently available drugs, almost 75% 
of patients required combination therapy after 2 years to achieve a suitable IOP reduction 
185. This is an indication that there is a need for more efficacious drugs and for new 
therapuetic targets. 
In this dissertation, newly synthesized cannabinoids, 0-1812 and 0-2545, were 
studied for their ability to decrease IOP and neuroprotective effects. The first aim with 
these new cannabinoids was to determine the pharmacokinetics after topical 
administration. Using in vivo microdialysis, continuous sampling of the aqueous and 
vitreous is possible to determine pharmacokinetic profiles of both the lipid (0-1812) and 
water soluble (0-2545) cannabinoids. After a single topical administration, 0-1812 
effectively penetrated both the anterior and posterior chamber and was maintained for at 
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least 120 min. 0-2545, being water-soluble, also penetrated both the ocular chambers, 
but was eliminated more rapidly than 0-1812. 
Before studying the IOP effects in the eye, a stable ocular hypertensive model that 
mimics human glaucoma had to be developed. Limitations with currently available 
models prompted us to develop a technique in which careful attention was given to 
minimizing surgical trauma, primarily by identifying the vortex vessels directly through 
the conjunctiva and then ligating them using only very small minimal incisions. We 
hypothesized that the greater the surgical insult, the faster and more extensive the 
development of collateral circulation, which would defeat the attempt to elevate IOP. It 
was crucial that incisions of the conjunctiva be limited to the immediate area of the 
vortex veins. Ligation rather than cautery of vortex veins was essential. Collateral 
circulation was more extensive when cautery alone or cautery following ligation was 
used. It is possible that the use of cautery alone is a sufficient local insult to stimulate the 
formation of collaterals. Following ligation of three of the four vortex veins, a steady 
elevation was achieved without negative impact on other ocular structures except for the 
retina. After ligation, IOP increased gradually and was sustained for up to a year. This 
Sprague Dawley rat model was also remarkably free of postoperative complications and 
responded well to standard pharmacotherapy with timolol. 
Using this ocular hypertensive model in specific aim # 2, the ability of newly 
synthesized 0-1812 and 0-2545 to decrease IOP was found to be comparable to or even 
greater than WIN 55212-2, a widely studied cannabinoid and timolol, a B-adrenergic 
blocker and first line agent in glaucoma medical therapy " . The ability of the 
cannabinoids to reduce IOP is mediated primarily by CB1 receptor activation. This can 
be concluded by using CB receptor specific antagonists. In the presence of CB1 
antagonist, SR141716, the magnitude and duration of cannabinoid mediated hypotensive 
effect was severely diminished. 
Once the potential to reduce IOP was realized, the neuroprotective effect of these 
O-compounds was studied in specific aim # 3. In this study the ERG was used as an end-
point to evaluate retinal function based on the a-wave amplitude. The ERG a-wave 
represents the outer retinal response, which is generated by the photoreceptors and 
bipolar cells ay'Ail. The a-wave amplitude was preserved after treatment with both O-
1812 and 0-2545 when compared to NMDA alone treatment. However, 0-1812 was 
more efficacious than 0-2545. Retinas from a subsection of animals were removed and 
examined histologically. Our ERG findings corroborated with histology. Although both 
O-compounds were equally efficacious in preventing retinal ganglionic cell loss, data 
from both IOP as well as ERG suggests that among the O-compounds, 0-1812 is more 
efficacious than 0-2545. 
In this study the electroretinogram was used as an end-point to evaluate retinal 
function based on the a-wave amplitudes. The ERG a-wave represents the outer retinal 
response which is generated by the photoreceptors and bipolar cells 89 '2U. The rods and 
cones with impulses from their respective bipolar cells contribute to the corneal positive 
and negative responses of the ERG a-wave 212. However, majority of the a-wave 
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amplitude is derived from the rods rather than the cones . The outer retinal response 
can be isolated by bright light stimulus 8 9 '2 n . Although this technique is gaining 
popularity, analysis and interpretation of ERG data are currently not standardized. We 
are solely relying on the amplitude changes of the a-wave and not the latency of the peak 
largely due to the fact that the exact mechanisms that generate the a- or b-waves have not 
been fully elucidated. As a result, these findings cannot be translated directly in the 
human glaucoma condition. In this experiment, discrepancies in ERG a-wave response 
after NMDA damage were obvious within the first week. In some instances, 
photoreceptor damage did not register electrically with the full-field system and therefore 
was not used as part of the analysis. Fortunately, after two weeks, ERG responses had 
stabilized and differences between the treated and untreated eyes could be easily 
quantitated. 
While this study solely focused on the health of the photoreceptors, the next 
logical step is to study the effects on the retinal ganglionic cells. The full-field ERG 
modality alone is not sufficient to assess ganglionic cell function, a more sophisticated 
ERG modality, such as a multifocal electroretinogram should be employed. With this 
technique, a functional map of the retina can be obtained in vivo. Regardless of the 
technological sophistication, the use of any ERG modality is still preferred over the 
conventional histological techniques because it is possible to monitor the progression of 
the disease as well as treatment effectiveness over time. A standard histological 
technique to count retinal cells involves an invasive procedure in which the optic nerve is 
transected and fluoro-gold injected at the transection site. The animal is then kept alive 
for 48 hrs after which it is euthanized and the retinas flat mounted. This technique 
introduces a myriad of variables, for e.g. during the 48 hrs, the animal is rendered blind 
and loses the ability to feed itself, the dye itself is absorbed into the brain causing other 
CNS deficits. All of these side effects are not desirable. 
Despite the currently available therapeutic approaches for the treatment of 
glaucoma, up to 50% of patients cannot be maintained on single drug therapy; most 
require use of two or even three drugs to control their IOP 9T. In additional experiments, 
the combined efficacy of cannabinoids with timolol, dorzolamide or brimonidine was 
compared in our rat glaucoma model. Travoprost was also used but did not change the 
IOP after a single dose. In this study, both 0-1812 and 0-2545 were most effacacious 
when administered alone. There were no synergistic or additive effects on IOP when 
combined with timolol, brimonidine or dorzolamide. Because of the efficacy of the O-
compounds, they hold tremendous potential as monotherapy in patients who do not 
respond to currently available medications. 
Glaucoma is a complex disease and its current limited therapeutic management 
suggests the need for neuroprotective intervention. While this neuroprotective strategy is 
sound, its realization requires dealing with complex signal transduction events that have 
unresolved mechanisms. However, data from this dissertation supports cannabinoids as a 
new class of drugs that have shown great potential for monotherapy, having both 
neuroprotective and anti-hypertensive effects. These initial observations need to be 
further confirmed in other animal models before they receive clinical evaluation. Future 
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investigations will focus on the determining the mechanisms of neuroprotection and 
development of new cannabinoid and non-cannabinoid analogs. 
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